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Abstract 
 
BIOPHYSICAL BASIS OF SKIN CANCER DETECTION USING 
RAMAN SPECTROSCOPY 
 
Xu Feng, Ph.D. 
The University of Texas at Austin, 2019 
 
Supervisor:  James W. Tunnell 
 
The goal of this dissertation is to study the potential of Raman spectroscopy in 
improving the clinical diagnosis of skin cancer, including two main applications: 
noninvasive screening of melanoma skin cancer and surgical margin detection of 
nonmelanoma skin cancer.  
Skin cancer is the most common type of malignancy, accounting for over 5.4 
million cases and 10 thousand deaths per year in the United States alone. Like most cancers, 
the current “gold standard” diagnosis relies on biopsy and histopathology, which is 
invasive, time-consuming, and costly. Moreover, large numbers of benign lesions are 
biopsied for melanoma diagnosis, resulting in substantial financial burden and patient 
discomfort. Therefore, an urgent need exists to develop a noninvasive, fast, and accurate 
method for skin cancer detection.  
The first part of the dissertation focuses on exploring the biophysical origin of in 
vivo melanoma detection. Our group has previously reported on the development of a 
clinical Raman spectroscopy system towards spectral biopsy of skin; however, the 
biochemical changes that Raman spectroscopy relies on for accurate melanoma diagnosis 
 viii 
remained unclear. As a result, we proposed a biophysical inverse model to address this 
issue. To build the model, we established a custom confocal Raman microscope to extract 
in situ human skin constituents spanning normal and various diseased states. Our results 
indicate collagen, elastin, keratin, cell nucleus, triolein, ceramide, melanin, and water are 
the most important model components. Furthermore, collagen and triolein are the most 
relevant markers to discriminate malignant melanoma from benign nevi.  
The second part of the dissertation discusses the biophysical basis of nonmelanoma 
skin cancer margin delineation. We discovered the diagnostic markers to accurately 
differentiate tumor from normal skin, which is critical to maximize positive patient 
outcomes in skin cancer surgery. The biochemical changes derived from our model were 
highly correlated with histopathological diagnosis. We further demonstrated the feasibility 
of a superpixel acquisition approach for rapid classification of tumor boundaries in skin 
biopsies. Our results suggest Raman spectroscopy will be a powerful tool for intraoperative 
surgical guidance. 
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Chapter 1: Introduction  
This chapter will start from an introduction of skin cancer, followed by the 
conventional method for skin cancer detection. Next, the optical methods will be 
introduced, including our primary research tool – Raman spectroscopy. The two main 
challenges of Raman spectroscopy in cancer research will be discussed, which becomes 
the motivation of this dissertation. Finally, this chapter will introduce the outline of this 
dissertation.  
1.1 BACKGROUND OF SKIN CANCER  
Skin cancer is the most common type of malignancy, accounting for over 5.4 
million cases and 10,000 deaths per year in the US alone [1]. Skin cancer can be divided 
into two types: melanoma and nonmelanoma skin cancer. Basal cell carcinoma (BCC) and 
squamous cell carcinoma (SCC) are the two most common types of nonmelanoma skin 
cancer. BCC accounts for approximately 75% of all skin cancers, while SCC makes up 
approximately 20% of all skin cancers. Although nonmelanoma skin cancer is usually not 
fatal, it can cause significant local damage and can metastasize if left untreated [2]. On the 
contrary, melanoma accounts for less than 2% of all skin cancer cases, but it contributes to 
a vast majority of skin cancer deaths. When detected at an early stage, most of the 
melanomas can be treated and cured by standard surgical excision. While at later stages, 
the risk of progression to lethal metastatic disease dramatically increases [3].  
1.2 STANDARD OF CARE IN SKIN CANCER DETECTION 
Detection is a general term that defines the action or process of identifying the 
presence of tumor. Current standard-of-care in skin cancer detection involves both 
screening and treatment.   
At present, the standard-of-care for skin cancer screening relies on visual inspection 
of suspicious lesions followed by biopsy and histopathology. The biopsies are performed 
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in a dermatologist’s office and then sent to the histopathology lab for further examination. 
A few additional days may be needed to deliver the final results. These biopsy procedures 
are invasive, inefficient, and inconvenient. More importantly, the process has low 
diagnostic accuracy (49-81% among dermatologists for melanoma [4]). The number of 
pigmented lesions needed to be excised to identify one melanoma, also called “negative 
biopsy ratio”, varies among dermatologists, new and experienced general practitioners [5]. 
The negative biopsy ratio varies between 6.3:1 and 8.7:1 by dermatologists, and between 
20:1 and 30:1 for general practitioners [6]. The negative biopsy ratio can be even higher 
for female patients and young patients (less than 30 years old) [7]. Large numbers of 
biopsies are performed on benign skin, leading to a substantial financial burden to the 
healthcare system and the patients. According to a recent study, the estimated cost of 
biopsied benign tumors ranges from $624 million to $1.7 billion [8]. As a result, a critical 
need exists to develop a noninvasive, accurate, fast, and inexpensive method for early skin 
cancer screening. 
The standard-of-care for skin cancer treatment is surgery. As to melanoma skin 
cancer, standard surgical excision or wide excision is commonly employed to remove the 
melanoma and a small margin of normal skin around it. The margin of normal skin depends 
on the thickness and location of the melanoma [9]. For nonmelanoma skin cancer, common 
types of surgery include standard surgical excision, Mohs micrographic surgery (Mohs), 
curettage and electrodesiccation, and cryosurgery [10]. Particularly, Mohs surgery is a 
precise surgical technique that aims to remove all the tumor cells, while preserving as much 
of the surrounding healthy tissue as possible. Mohs surgery is by far the most effective 
treatment for high-risk BCC and SCC. According to one study, the 5-year recurrence rate 
of Mohs is 1 – 3% for primary BCC and 5 – 7% for recurrent BCC. In contrast, the 5-year 
recurrence rate of standard surgical excision is 3 – 10% in primary BCC and >17% in 
recurrent BCC [11].  
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1.3 OPTICAL TECHNIQUES FOR SKIN CANCER DETECTION 
The maturing of photonic technologies has created an opportunity to develop the 
optical biopsy – a minimally invasive or noninvasive alternative to the traditional biopsy. 
The basic principle of optical biopsy is to interact with a tissue using light, and then decode 
the returned signal containing the characteristic of the tissue.  
Ideally, an optical biopsy needs to meet four main requirements in order to achieve 
the maximum clinical significance. An optical biopsy needs to have (1) high resolution to 
reveal cellular or subcellular content; (2) high speed for real-time measurement; (3) high 
penetration depth to investigate a lesion in three-dimension; (4) molecule-specific and 
label-free detection [12]. Unfortunately, optical techniques can hardly meet all the 
requirements, because interrelationships exist among those requirements. For example, in 
spectroscopic field, high resolution imaging often results in slow acquisition speed. High 
resolution image acquired at high speed is often at the tradeoff of the spectral content. 
Another tradeoff exists between penetration depth and resolution: improving axial 
resolution may decrease the maximum possible imaging depth, as in the case of optical 
coherence tomography.  
The remainder of this section will introduce several optical biopsy methods that 
have demonstrated to be promising in skin cancer detection. They are divided into non-
spectroscopic techniques (including reflectance confocal microscopy, coherence optical 
tomography, two-photon-excited fluorescence, second-harmonic generation), and 
spectroscopic techniques (including diffuse reflectance, laser-induced fluorescence, 
infrared, and Raman spectroscopy). All the methods introduced here are label-free, so 
techniques such as surface-enhanced Raman scattering (SERS) [13-15] that involves 
exogenous enhancement mechanism are not within the scope of this introduction.  
1.3.1 Non-spectroscopic Techniques 
Reflectance confocal microscopy (RCM) allows for the evaluation of skin at the 
cellular level (0.5 – 1.0μm lateral resolution, and 1 – 3μm optical sectioning). The basic 
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contrast mechanism is the changes in refractive index. RCM has become a valuable adjunct 
to dermoscopy, and has been successfully translated from benchtop to bedside (Vivascope 
1500 and Vivascope 3000 (a handheld version), Caliber I.D. Inc., Rochester, NY, USA) 
[16-18]. RCM is a promising tool for the diagnosis of melanocytic lesions. RCM is 
particularly accurate for light-colored lesions (specificity was 39% for dermoscopy and 
84% for RCM) [19]. In a preliminary study, a sensitivity/specificity of 94%/94% was 
obtained for detecting BCC cancer margin [20]. Limitations of RCM include: (1) limited 
imaging depth of approximately 250μm, so information deeper than the upper reticular 
dermis cannot be captured; (2) time required to scan and training needed to read the images; 
(3) low contrast of nucleus as compared to hematoxylin and eosin (H&E) histopathology. 
To solve (3), aluminum chloride is routinely used to enhance for nuclear contrast. 
Aluminum chloride generates compaction of chromatin, which can result in increased 
backscatter and brightening of nuclear morphology [17, 18].  
Optical coherence tomography (OCT) imaging also detects the changes in 
refractive index. OCT is the optical analog of ultrasound. One major advantage of OCT is 
it can provide real-time 1D depth, 2D cross-sectional, and 3D volumetric images in real-
time. Besides, OCT has a deep penetration depth. Frequency domain OCT can probe as 
deep as 2mm with enough cellular clarity to diagnose nonmelanoma skin cancers [21]. 
OCT has demonstrated promising outcomes by enabling accurate margin mapping of 
nonmelanoma skin cancer in advance of Mohs micrographic surgery [22]. In another study, 
OCT can predict BCC with an overall sensitivity of 89% and specificity of 60% [23]. OCT 
has been combined with RCM in a handheld device for detecting and delineating the 
margins of BCC in vivo. The result demonstrated that using combined OCT and RCM 
facilitated the identification of superficial and nodular BCCs, as well as lateral and deep 
margins [24]. Despite of the success, the technical challenges associated with OCT have 
limited its application in oncology. For instance, large volumes of tissue need to be imaged 
at high cellular resolution to detect cancer. Besides, OCT image interpretation may also be 
challenging for oncologists [25].  
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Two-photon-excited fluorescence (TPEF), and second-harmonic generation (SHG) 
are the two major types of nonlinear optical imaging tools. TPEF and SHG both depend on 
simultaneous interaction of two photons with the tissue. Different from TPEF, SHG does 
not have energy loss, so the excited photon has exactly twice the energy of the interacting 
photons (thus the emission frequency is the twice of the excitation frequency). The contrast 
mechanism of TPEF is the endogenous fluorescent molecules found in tissues, such as the 
mitochondrial matrix protein nicotinamide adenine dinucleotide (NADH), flavin adenine 
dinucleotide (FAD), the structural proteins elastin, keratin, and collagen, and the pigments 
melanin. On the contrary, SHG is highly sensitive in detecting collagen fibers, a clinically 
relevant biomarker. TPEF, SHG, combined with coherent anti-stokes Raman scattering 
(CARS) can be used to generate H&E-like histopathology to differentiate BCC and SCC 
from normal skin [26]. In another study, TPEF was used to examine the pigmented 
melanoma in human in vivo. By using a six-axes diagnostic matrix and machine learning, 
benign nevi could be distinguished from melanoma with 75% sensitivity and 80% 
specificity [27]. A recently developed nonlinear optical imaging platform can 
simultaneously acquire autofluorescence, and second/third harmonic generation from a 
single excitation source. This technique has been successfully used to image cellular and 
extracellular components, and may be a promising tool in cancer research [28].  
1.3.2 Spectroscopic Techniques 
As mentioned earlier in this chapter, one significant aspect of optical biopsy is 
obtaining molecule-specific information. Molecular contrast is typically achieved by 
spectroscopy. Major spectroscopic techniques for cancer detection include diffuse 
reflectance, laser-induced fluorescence, infrared, and Raman spectroscopy.  
Diffuse reflectance spectroscopy (DRS) and laser-induced fluorescence 
spectroscopy (LIFS) detects the optical scattering, absorption and fluorescence properties 
of sampled tissue. Because the physiological parameters of the tissue are associated with 
the progression of disease, DRS and LIFS provides a quantitative and objective 
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measurement for tissue diagnosis. A previous study in our lab found a significantly lower 
amount of scattering and higher amount of absorption parameters in cancerous lesions as 
compared to normal skin. The clinical DRS-LIFS system classified BCC with a 
sensitivity/specificity of 94%/89% [29]. In another clinical study, oblique incidence DRS 
system distinguished malignant melanoma with 90% sensitivity and specificity, and also 
classified BCCs and SCCs with 92% sensitivity and specificity [30].  
   Infrared (IR) and Raman spectroscopy are two major vibrational spectroscopic 
techniques. Although both techniques can provide chemical composition and molecular 
structural information in cells and tissues, their physical mechanisms are fundamentally 
different. Raman spectroscopy is due to the inelastic scattering of light by the molecular 
vibrations, while IR spectroscopy results from the absorption of light. Water is an 
extremely strong absorbing medium for IR spectroscopy. To bypass the water absorption 
obstacle, sample is commonly either sliced into micrometer sections for transmission 
measurements, or measured under attenuated total reflection [31]. Therefore, IR is 
preferably used as a visualization tool to aid pathologists in assessing tissue specimens 
[32]. Fourier transform IR has been successfully translated into clinic for rapid all-digital 
histopathology of human breast and prostate sections [33, 34].  
Raman spectroscopy is first observed by Indian Nobel Laureate C.V. Raman in 
1928 [35]. The first biological application was reported in 1970 [36]. Spontaneous Raman 
scattering is weak, and always comes with the Rayleigh scattering light and tissue 
autofluorescence. In the recent decades, advances in near-infrared lasers, optical filters, 
fiber optics and CCD cameras have greatly improved its sensitivity in detecting the 
chemical composition of biological tissues. For instance, Rayleigh scattering light can be 
well separated from Raman scattered light using a high optical density notch filter, and 
tissue autofluorescence can be greatly reduced by using near-infrared excitation.  
Raman spectroscopy has the following advantages: First, it is highly sensitive and 
specific to the alternations in molecular signatures (lipids, proteins, DNA, etc.). For 
instance, Kochan et al. used Raman imaging to detect the changes of lipid droplets content 
7 
 
in fatty liver disease, and found that the drug treatment resulted in an increased degree of 
unsaturation of lipids forming droplets in a mouse model [37, 38]. Those molecular 
signatures can in turn be correlated with tissue pathology or physiology for diagnosis. 
Bergner et al. used Raman imaging to correlate the concentration of proteins, lipids, nucleic 
acids, and lipid to protein ratios with the glioma brain tumor grades [39]. Secondly, Raman 
spectroscopy is minimally-invasive and label-free, making it a safe and attractive tool for 
clinical applications. Finally, it can provide an objective diagnosis with minimum tissue 
processing [40, 41].  
Raman spectroscopy has also been combined with other optical biopsy tools to 
improve diagnosis. For instance, a combination of Raman spectroscopy with reflectance 
confocal microscopy has been used to explore the in vivo water concentration profiles and 
natural moisturizing factor for the stratum corneum [42]. Raman spectroscopy has been 
combined with three label-free nonlinear imaging modalities (CARS, TPEF, and SHG) to 
generate H&E-like images [43]. Raman spectroscopy has also been integrated with optical 
coherence tomography (Raman-OCT system) to precisely visualize tissue morphology and 
simultaneously determine tumor type [44]. OCT image can provide an initial 
morphological analysis of the lesion, and then guide acquisition of biochemically specific 
Raman data [45, 46].  
1.4 CHALLENGES OF RAMAN SPECTROSCOPY IN CANCER RESEARCH 
Although Raman spectroscopy is promising in cancer detection, it has several well-
understood shortcomings that must be overcome so that it can become a reliable and 
common diagnostic tool. This involves two main challenges: (1) exploring the biophysical 
origin of Raman detection, and (2) increasing the acquisition speed. These challenges 
become the motivations of this dissertation.  
1.4.1 Revealing the Biophysical Origin  
The first challenge of Raman spectroscopy (or optical biopsy methods in general) 
in cancer research is unveiling the biophysical basis of detection. For image-based 
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detection, the challenge exists in interpreting the images in a way that a pathologist is 
familiar reading. In traditional detection method, tissue samples are commonly stained 
using hematoxylin and eosin (H&E) stain to review by a pathologist. The hematoxylin 
stains the nuclei of a cell blue, and eosin stains the extracellular matrix and cytoplasm pink. 
However, optical imaging modalities rely on different contrast mechanisms, thus 
substantial training is required to read the images. To identify basal cell carcinoma from a 
reflectance confocal image, pathologists were trained to read five criteria, such as the 
presence of elongated monomorphic basaloid nuclei, increased vasculature, and prominent 
inflammatory infiltrate [47].  
Machine learning and deep learning have opened up a new era in image-based 
cancer detection. Digitally stained histopathology has been developed for various optical 
imaging modalities. Examples are autofluorescence [48], Fourier Transform infrared 
spectroscopy [49], and nonlinear microscopy [50-52]. Furthermore, machine learning and 
deep learning make it possible to automatically classify the images for presence or absence 
of cancer [33, 53, 54].  
In contrast, spectrum-based detection is commonly achieved by fiber probe-based 
approaches. To date, most fiber probe-based approaches have used statistical algorithms to 
describe the spectral differences of Raman spectra, such as principal component analysis 
(PCA) [55] and independent component analysis (ICA) [56]. However, those statistical 
methods are like “black box” – the principal or independent components are difficult to 
relate to the biophysical origin of disease, such as the microstructural organization of 
proteins and lipids and the functional state of cellular metabolism. These microstructural 
changes are what pathologists and dermatologists use to make diagnostic decisions and 
decide on the most appropriate treatment [57].  
1.4.2 Increasing the Acquisition Speed  
The fundamental limitation of spontaneous Raman spectroscopy is the small 
Raman scattering cross-section, which is on the order of 10-30 cm2 per molecule [58]. 
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Therefore, integration time needs to be long enough to generate a Raman spectrum with 
acceptable signal-to-noise ratio. The typical integration time is ~1s for tissue. Using higher 
laser power can reduce the integration time, but may lead to tissue damage.  
One solution is to use Raman optical fiber probe for large-volume screening. The 
sampling volume is typically on the order of mm3, but can vary depending on the probe 
design. For instance, the sampling depth of spatially offset Raman spectroscopy in on the 
order of cm, while a confocal probe is on the order of 10 – 100μm [59]. Raman optical 
fiber probe is preferably used in pointwise sampling mode rather than the imaging mode. 
Raman optical fiber probe has allowed for fast and accurate cancer diagnostics, including 
ex vivo study of breast [60, 61], prostate [62], lung [63] and skin [64, 65], and in vivo study 
of breast [57], cervical [66], and skin [4, 67].  
Another solution is to use coherent Raman scattering (CRS) microscopy to for rapid 
label-free imaging. Different from spontaneous Raman scattering, which depends on 
spontaneous interactions, the Raman processes in coherent Raman scattering are driven 
coherently, leading to an enhancement of the scattering signals by several orders of 
magnitude [68]. Two types of coherent Raman scattering have been developed favorably 
for biomedical applications: coherent anti-stokes Raman scattering (CARS) [69], and 
stimulated Raman scattering (SRS) [70]. While spontaneous Raman scattering involves 
only a pump beam as the excitation source, coherent Raman scattering involves both the 
pump beam and Stokes beams, where the difference in frequency between the two beams 
is tuned to match molecular vibrations of interest [58].  
CARS is commonly combined with second harmonic generation and multiphoton 
fluorescence to generate label-free chemical imaging. By using intrinsic signals from CH2 
and CH3 vibrations of lipids and protein, high resolution images can be generated for 
various tissue types, including brain [71, 72], skin [26, 73], lung [74], and liver [75, 76]. 
An in vivo CARS endoscope has been developed for real-time histopathology diagnosis 
[77].  
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SRS is developed more recently and offers further several advantages over CARS: 
(1) it does not have non-resonant background; (2) the Raman spectrum is identical to 
spontaneous Raman spectrum, but with a much narrower range; (3) the signal and 
concentration of target molecules have a linear relationship [78]. One highlight of in vivo 
SRS is its application to brain tumor margin assessment [79]. A 97.5% sensitivity and 
98.5% specificity were achieved in detecting brain tumor infiltration in human [80]. SRS 
microscopy built upon fiber laser source also has the promise to facilitate the use for 
clinical applications [81, 82].  
Spontaneous Raman spectroscopy allows for acquiring full spectrum content, and 
has much simpler and less inexpensive setup. Therefore, techniques have also been 
developed upon spontaneous Raman spectroscopy for rapid measurement. Examples to 
speed up spontaneous Raman acquisition include line-scan [83], wide-field imaging [84], 
Weiner estimation [85], multi-focal array [86], and DuoScan [87]. Line-scan Raman 
spectroscopy used cylindrical lens to generate a uniform laser line of approximately 100 
μm [83], and simultaneously record the Raman spectra on the line using a two-dimensional 
imaging sensor [88, 89]. Wide-field Raman spectroscopy used a fiber bundle array as the 
collection fibers combined with a tunable filter to generate fast images [84]. Weiner 
estimation method could rapidly reconstruct full Raman spectrum at each pixel of the 
Raman narrow-band image. Multi-focal array method used micro-lens [90], scanning 
galvanometer mirrors [86], or spatial light modulator [91, 92] to generate multipoint 
illumination. DuoScan method generated a square illumination by continuously scanning 
the laser beam, and was used to characterize human bone composition [93].  
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1.5 OVERVIEW OF DISSERTATION STUDY 
The goal of this dissertation is to study the potential of Raman spectroscopy in 
improving the clinical diagnosis of skin cancer. We addressed two main challenges of 
Raman spectroscopy in cancer research as mentioned in Chapter 1.4: we explored the 
biophysical origin of accurate melanoma and nonmelanoma skin cancer detection, and we 
expedited Raman acquisition for rapid skin cancer surgical margin assessment.  
In an effort to explore the biophysical origin, we proposed a biophysical human 
skin cancer model in Chapter 2. Our model is innovative because the model components 
are in situ skin constituents extracted from fresh human skin sections spanning normal and 
various disease states. In order to extract in situ skin constituents, we built a custom 
confocal Raman microscope integrated with a reflectance confocal microscope. Chapter 
2 resulted in eight Raman active biomarkers to describe the spectral differences of various 
skin pathologies.   
In Chapter 3, we applied our biophysical model for the first time to an in vivo 
clinical melanoma dataset. Our lab has previously developed a fiber-probed based clinical 
system [94], and achieved high accuracy in detecting malignant melanoma from benign 
nevi [67]; however, the biophysical origin of accurate in vivo melanoma detection remains 
unclear. One of our key findings is that collagen and triolein are the most relevant 
diagnostic markers to discriminate melanoma from benign nevi. Our results would increase 
fundamental knowledge of cancer processes as well as lay the groundwork for improving 
the diagnostic performance of the technology. 
 In Chapter 4, we explored the biophysical basis of ex vivo nonmelanoma skin 
cancer surgical margin detection. Although previous studies have demonstrated that 
confocal Raman microscope is highly accurate in detecting the tumor margins of basal cell 
carcinoma, the biophysical basis of this accurate detection remains unclear. Therefore, we 
discovered the most relevant diagnostic markers for accurate discrimination of basal cell 
carcinoma from surrounding normal tissues. The biophysical changes derived from our 
model was consistent with histopathological diagnosis. 
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Chapter 5 describes a superpixel acquisition method to overcome the technical 
hurdle of traditional Raman imaging in speed. We then applied this method for the first 
time to rapid skin cancer surgical margin assessment. Our findings suggest that Raman 
spectroscopy is a promising surgical guidance tool for identifying tumors in the resection 
margins. 
We conclude this dissertation in Chapter 6. 
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Chapter 2: Establishing a Raman biophysical inverse model for skin 
cancer detection1 
2.1 INTRODUCTION 
This chapter describes a novel Raman “biophysical model” of human skin cancer. 
The morphological and biochemical composition of skin tissue are derived from the model, 
and then used to classify skin cancers.  
Previous biophysical models used model components either measured directly from 
synthetic/purified chemicals [65, 95-98], or extracted from tissue sections in situ [39, 99, 
100]. The advantage of using synthetic/purified chemicals as model components is that 
they can be easily measured without the need for Raman imaging. This concept has been 
applied successfully to a previous Raman model of excisional skin biopsies [65] and has 
given us some prior knowledge about skin composition. Other groups used in situ 
constituents to build biophysical models of other disease processes, such as coronary 
atherosclerosis [99], breast cancer [100], and brain tumor [39].  
Here, we expand upon this approach by developing a biophysical human skin model 
using in situ skin constituents. In situ constituents better represent the milieu of biological 
tissues that cannot be recapitulated in a synthetic environment. In human skin many 
constituents are present in various forms and each has a slightly different Raman spectrum. 
For instance, both collagen type I and III are abundant in human dermis; however, if both 
of them are included in the model, it may lead to overfitting and unstable results. In 
addition, skin constituents synthesized in the lab or from commercial sources are not in 
their natural states as in the human skin. For instance, the Raman features of a protein may 
change when it is exposed to organic solvents during synthesis. As a result, a single 
spectrum of skin constituent extracted from its microenvironment can provide a more 
 
1Portions of this chapter are adapted from X. Feng, A. J. Moy, H. T. Nguyen, J. Zhang, M. C. Fox, K. R. 
Sebastian, J. S. Reichenberg, M. K. Markey, and J. W. Tunnell, "Raman active components of skin cancer," 
Biomedical optics express 8, 2835-2850 (2017). 
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general picture of the biophysical origins of skin spanning normal and abnormal disease 
states. 
Furthermore, we applied the model for the first time to in vivo human skin cancer 
screening data that covers a wide range of normal, nonmelanoma and melanoma skin 
cancers and precancers [67]. Previous Raman models of human skin were either built for 
ex vivo tissue specimens [65] or in vivo normal skin [101]; however, Raman biophysical 
models have not been applied to in vivo skin cancer screening to interpret biophysical 
changes between pathologies.  
In this chapter, we performed Raman imaging of tissue sections using a custom 
confocal Raman microscope. Multivariate curve resolution (MCR) analysis [102] was used 
to resolve in situ skin constituents from Raman images. Our results suggest that eight skin 
constituents are the most relevant building blocks, illustrating some variances with their 
corresponding synthetic components. The basis spectra of those skin constituents were then 
combined linearly to describe in vivo human skin spectra. The fit coefficients provided 
insight into the biochemical and structural composition of normal, benign and malignant 
skin tissues. Our model revealed the most important skin constituents representing the 
spectral features of skin tissues, and provided significant guidance to develop diagnostic 
algorithms for real-time noninvasive skin cancer diagnosis in future. 
2.2 MATERIALS AND METHODS 
2.2.1 Raman Instrumentation 
Raman images were collected with a custom-built confocal Raman microscope 
illustrated in Figure 2.1. The system was also integrated with a reflectance confocal 
microscope (RCM) and a bright-field microscope, which provided the morphology image 
for assisting in locating the region of interest for Raman imaging.  
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Figure 2.1: Schematic of confocal Raman and confocal laser-scanning microscope 
used for skin measurements. The flip mirror and CMOS camera were used 
for bright-field imaging. ISO, isolator; D1, D2: dichroic mirror; P1 – P3: 
pinhole; L1 – L6, lens; GM, galvanometer mirror; FM, flip mirror. 
 
The Raman excitation source was an 830nm single mode diode laser (LM830-
PLR200, Ondax). The laser beam was reshaped, expanded and delivered to the sample 
through a microscope objective (Olympus, NA = 1.2, 60x). The galvanometer mirror 
performed 2D raster scanning on the tissue. The backscattered Raman signal was collected 
by a spectrograph (f/1.8i, Kaiser) and a deep cooling CCD camera (IDUS, Andor) through 
an optical fiber (50 μm, NA=0.22), which also acted as a pinhole. The Rayleigh scattering 
light was collected by a PMT (C10709, Hamamatsu), and amplified by a current 
preamplifier (SR570, Stanford Research Systems). A data acquisition board (PCIe-6351, 
National Instruments) and LabVIEW software (National Instruments) were used to control 
the system. The power delivered to the sample was approximately 45mW. Lateral 
resolution was measured from the FWHM (full width at half maximum) of the point spread 
function using 0.2 and 0.5 μm microbeads. Axial resolution was measured from the FWHM 
of the intensity profile by translating a mirror towards the objective. The lateral, axial and 
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spectral resolution of the Raman system was around 1 μm, 8 μm and 8 cm-1, respectively. 
A more detailed characterization of the system can be found in Appendix A.  
2.2.2 Tissue Preparation and Raman Imaging 
Our study was approved by the Institutional Review Board at The University of 
Texas at Austin and Seton Medical Center. Fresh frozen human skin tissue samples were 
acquired from biopsy specimens during routine skin cancer surgery at Austin Dermatologic 
Surgery Center. After being transferred to the lab, the samples were stored at -80C. They 
were then thawed to -22C in a cryostat and sliced into 10 μm thin sections. The sections 
were transferred to magnesium fluoride slides (Edmund Optics) for the Raman 
measurement, and serial sections were transferred on standard microscope slides for 
hematoxylin and eosin (H&E) staining. Prior to Raman imaging, the sections were warmed 
to room temperature and kept moisturized with 0.9% saline solution.  
Next, we performed Raman imaging on skin sections. Typical integration time at 
each pixel location was 2s. Typical step size in both the x and y directions was 1μm, but 
sometimes to achieve a large of view a step size of 5 μm was used. Imaging area varied 
from 30×30 μm2 to 150×150 μm2. We then correlated the Raman image with the 
histopathology image of the serial stained section. A board-certified dermatologist assisted 
in identifying and confirming the morphology and biochemical components measured. In 
total, we collected more than 40 Raman images from samples of different disease states, 
including 24 images from 11 basal cell carcinoma (BCC) patients, 15 images from 5 
squamous cell carcinoma (SCC) patients and 4 images from 1 malignant melanoma (MM) 
patient.  
2.2.3 Data Preprocessing and MCR Analysis 
Raman data preprocessing was performed using MATLAB (R2015b, MathWorks). 
All spectra underwent wavelength calibration, background subtraction, cosmic ray removal 
and smoothing. The system spectral response was calibrated using a tungsten halogen lamp 
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(LS-1-CAL, Ocean Optics). The fluorescence background was then removed by modifying 
a 5th order polynomial fitting routine [103]. The effective spectral range was 800 to 1800 
cm-1.  
A multivariate curve resolution (MCR) method was employed to resolve individual 
morphological or biochemical components from the Raman image. This method has been 
successfully applied to stimulated Raman imaging data by Zhang et al. [104]. The basic 
concept of MCR is to decompose the raw spectra matrix D (unfolded from Raman imaging) 
into the product of two smaller matrices C and ST by a bilinear model: 
 
 𝐷 = 𝐶 ∙ 𝑆𝑇 + 𝐸 (2.1) 
 
𝑆𝑇 corresponds to the matrix of the pure spectra, 𝐶 is the related concentration 
profiles for each of the components and E is the error matrix. As an unsupervised learning 
method, the number of components contributing to 𝐷  was determined either by prior 
knowledge or by assessing the results obtained using singular value decomposition (SVD). 
After initial estimation is given for 𝑆𝑇, the 𝐶 and 𝑆𝑇 are optimized iteratively using an 
alternative least-squares algorithm (ALS) until convergence is reached.  
Here, we used a MATLAB based MCR-ALS toolbox [102] to determine 𝐶 and 
𝑆𝑇. The initial estimates of 𝐶 and 𝑆𝑇 were determined by means of a purest variable 
detection method [105]. The basic idea is to resolve highly overlapping near-infrared 
spectra with baseline problems by using the second-derivative spectra [105]. A 
nonnegative constraint and a 10% of tolerance were added to the ALS optimization. The 
concentration images for each individual component were reconstructed from 𝐶, and the 
corresponding basis spectra were obtained from 𝑆𝑇. We then categorized the basis spectra 
according to their biochemical or structural origin, such as elastic fibers, collagen fibers 
and cell nucleus.  
We obtained a library of basis spectra from various skin sections spanning normal 
skin, and various skin disease states. The spectra in the same category were then averaged 
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to create a single basis spectrum to represent that biochemical or structure. Although the 
basis spectra collected from different patients had minor differences, after averaging 
spectra from many patients we could ensure that the inter-patient variation was minimized.  
2.2.4 Clinical Screening Data Description 
In vivo human skin spectra came from our previous skin cancer screening study 
[67]. Data were collected from an optical fiber probe [106] integrated in a multimodal 
spectroscopy system [94] on different sites, such as scalp, nose, earlobe, shoulder and 
thigh. Lesion types including basal cell carcinoma (BCC, 19 lesions), squamous cell 
carcinoma (SCC, 38 lesions), actinic keratosis (AK, 14 lesions), benign pigmented lesion 
(PL, 17 lesions) and malignant melanoma (MM, 12 lesions). BCC and SCC are the most 
common types of nonmelanoma skin cancers, whereas AK and PL are the most common 
precancers of SCC and MM, respectively. Raman spectra of adjacent normal skin for each 
individual lesion were also collected. Although normal skin measurements were not 
verified by histopathology, they were visually verified to be normal by an experienced 
dermatologist/physician assistant.  
2.2.5 Model Establishment 
A sample’s Raman spectrum can be represented as a linear combination of the 
Raman spectra of the sample’s individual constituents. The signal intensity is then 
proportional to the chemical concentration [107]. Therefore, if one knows the spectra of 
the basis tissue constituents a priori, one can determine the concentration of those basis 
constituents. We used linear least-squares fitting with a nonnegative restraint for model 
fitting, according to the following equation: 
 
 𝑋 = 𝑐 ∙ 𝑠 + 𝑒 (2.2) 
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While  𝑋 is the sample’s spectrum (in vivo human skin spectrum). 𝑠 is the spectra 
matrix of the sample’s individual constituents. 𝑐 is the relative spectral contribution (fit 
parameter) predicted by the model. 𝑒 is the noise related with the clinical Raman system. 
Next, a combination of forward selection and backward elimination methods was 
performed to derive the most relevant basis constituents to the spectroscopic model. 
Finally, after applying the model to all the in vivo human skin data, we could obtain the 
biochemical and structural makeup of tissues spanning normal and various disease states.  
One important factor that may influence the performance of the model is 
collinearity of the basis spectra. Collinearity is a common issue in linear regression that 
may lead to an unstable result [108]. The following equation is to calculate the collinearity 
coefficients 𝑅 between two basis spectra, 𝑥 and  𝑦: 
 
 
𝑅 =  
𝑥𝑇𝑦
(𝑥𝑇𝑥)(𝑦𝑇𝑦)
  
(2.3) 
 
A value of 0 means the two basis spectra 𝑥 and 𝑦 do not have collinearity, and 1 
indicates the two vectors are the same. This equation was used for the initial evaluation of 
the model components.  
2.3 RESULTS 
2.3.1 Extraction of Primary Skin Constituents in Situ 
The basis spectra were categorized into: (1) cellular components, (2) epidermal 
extracellular matrix (ECM), (3) dermal ECM, (4) lipids, (5) pigments, and (6) 
miscellaneous. We will illustrate each category in the following part of this section.  
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2.3.1.1 Cellular Components 
To identify cellular tumor components, Raman imaging was performed within a 
tumor cluster in a BCC section (Figure 2.2). Using MCR analysis, we reconstructed three 
concentration images (Figure 2.2 a-c) corresponding to cell nucleus, cell cytoplasm, and 
the Raman substrate. Those structures correlated well with the bright field, RCM, and 
histopathology images (Figure 2.2 d-f), and their Raman spectra had similar characteristic 
peaks with the known spectra measured from the pure chemicals (Figure 2.2). This 
approach was used to resolve the other skin constituents in the following sections as well. 
As seen from the plots on the right, the basis spectra of in situ nucleus and synthetic DNA 
(Sigma-Aldrich) are similar, which both have the pronounced contribution from 
phosphodioxy group PO2
-1 at 1093 cm-1. However, the difference spectrum shows that in 
situ nucleus has substantial differences from synthetic DNA. For example, in situ nucleus 
appears to have a higher contribution from DNA backbone at 835 cm-1 [109]. 
The spectra of in situ cytoplasm and synthetic actin also have high similarity, but 
major differences can be found at 1003 cm-1 phenylalanine peak, 1081 and 1092 cm-1 lipid 
band. Numerous other peaks can also be appreciated in the difference spectra. These 
differences indicate the morphologically derived basis spectra of nucleus and cytoplasm 
include features related to other elements found in the cell.  
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Figure 2.2: Extracting cellular components from a BCC lesion. Raman images of 
nucleus (a) and cytoplasm (b) and Raman substrate (c) are compared with 
bright-field image (d), RCM image (e) and histopathology image (f). The 
boxes on (e) and (f) mark the location of Raman imaging. The contrast of 
the RCM image was provided by the relative difference in refractive index 
of cells and the surrounding stroma. Plots on the right show Raman 
spectra of in situ nucleus, synthetic DNA and their difference spectrum. 
Also in situ cytoplasm, synthetic actin and their difference spectrum. Scale 
bar: 10 μm. 
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2.3.1.2 Epidermal ECM 
The epidermal layer of skin provides the barrier to water permeation and abrasion 
resistance. It is produced by continuous cell division of keratinocytes in the basal layer. 
Ultimately, the keratinocytes cornify and produce the stratum corneum, which is the dead, 
flattened cells at the outermost layer of the skin [110]. Because keratin is the main chemical 
component of epidermal ECM, we use in situ keratin to represent epidermal ECM.  
 
Figure 2.3: Extracting the epidermal component from a normal skin section. Raman 
images of in situ keratin (a) and Raman substrate (b) are compared with 
bright-field image (c) and histopathology image (d). Plots on the right 
show Raman spectra of in situ, synthetic keratin and their difference 
spectrum. Scale bar:10 μm. 
 
Figure 2.3 illustrates Raman imaging performed on epidermis from a normal skin 
section. Tissue architecture correlates well with the histopathology image. The 
concentration images of epidermal ECM and the Raman substrate were reconstructed using 
MCR analysis. The Raman spectra of in situ and synthetic keratin are similar with 
substantial differences found at the protein bands at 855, 1318 and 1409 cm-1 [111].   
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2.3.1.3 Dermal ECM 
Dermal ECM comprises fibrillar collagens and associated proteins. Collagen fibers 
account for about 70% of the weight of dry dermis, while elastin maintains skin elasticity 
through a durable cross-linked array. Large diameter elastin-rich elastic fibers reside in the 
reticular dermis [112].  
Figure 2.4 illustrates Raman imaging performed on a BCC skin section to extract 
dermal ECM proteins. The in situ collagen (collagen fiber), in situ elastin (elastic fiber), 
dye, and Raman substrate were resolved from the image by MCR analysis. The thin blue-
gray elastic fibers and the pink collagen fibers can be identified from the histopathology 
image. The plots on the right compares the Raman spectrum of in situ collagen with 
synthetic type I and III collagen. Major differences are found at 856, 1248 and 1665 cm-1 
protein bands between in situ and type I collagen, and 1157 and 1514 cm-1 between in situ 
and type III collagen. In situ and synthetic elastin have very similar spectra, which indicates 
that elastin is the major chemical component of elastic fibers.  
2.3.1.4 Lipids 
Skin’s epidermal surface is comprised of sebaceous and stratum corneum lipids. 
Epidermal lipids act like a cement to fill the spaces between the cells. The major 
constituents of sebaceous lipids are triglycerides (triolein), wax esters and squalene, while 
the epidermal lipids are a mixture of ceramides, free fatty acids and cholesterol [42, 113]. 
Ceramide is an important epidermal surface lipid as it composes almost half of the SC 
lipids [110].  
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Figure 2.4: Extracting dermal components from a BCC skin section. In situ collagen 
(a) and elastin (b) are resolved from the image. The dye used by the 
dermatologist to mark the orientation of the tissue was also detected (c). 
Raman images are compared with the bright-field image (d), RCM image 
(e) and histopathology image (f). The box on (e) marks the location of 
Raman imaging. The arrow in (f) points to a thin blue-gray elastic fiber. 
Plots on the right displays Raman spectrum of in situ collagen, synthetic 
collagen and the difference spectrum. Also Raman spectrum of in situ 
elastin, synthetic elastin, and their difference spectrum. Scale bar: 10 μm.  
 
Raman imaging was also performed to derive the basis spectra of lipids. Figure 2.5 
illustrates extracting in situ ceramide and triolein within a hair follicle from a SCC skin 
section. The synthetic spectra are not shown because they look similar to in situ spectra. 
Instead, we compare the difference spectra between in situ lipids. Although in situ ceramide 
and palmitic acid look similar, they have different spectral intensity in C-C stretching mode 
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at 1063 and 1128 cm-1, CH2 twisting mode at 1296 cm
-1, CH2 bending mode at 1440 cm-1 
and C=C stretching mode at 1656 cm-1. Larger variance was observed in those bands 
between in situ ceramide and triolein. Triolein is not only abundant in skin lipid, but also 
in subcutaneous fat [100]. As triolein has a very strong Raman scattering cross-section, it 
contributes greatly to Raman spectrum of human skin.  
 
 
Figure 2.5: Extracting lipids within a hair follicle from a SCC skin section. In situ 
ceramide (a), triolein (b) and Raman substrate (c) are resolved from the 
image. Raman images are compared with the bright-field image (d), RCM 
image (e) and histopathology image (f). Some lipids in (f) were lost during 
the staining processing. The box on (e) and (f) marks the location of 
Raman imaging. Difference spectrum between in situ ceramide and 
palmitic acid and difference spectrum between in situ ceramide and 
triolein are also shown. Scale bar: 10 μm. 
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2.3.1.5 Pigments 
Skin pigments include melanin and beta carotene. Melanin is produced by 
melanocytes in the basal layer of the epidermis. In Figure 2.6, we identified melanin from 
a MM skin section. As expected, melanin provides strong contrast in RCM image [114]. 
We lowered the laser excitation to 20mW to reduce tissue burning caused by strong 
absorption of melanin. As this led to a worsening in the SNR, we further smoothed the 
melanin spectrum by fitting it to Gaussian functions [115]. The two broad peaks located at 
1378 cm-1 and 1573 cm-1 were consistent with the spectrum of in vivo cutaneous melanin 
[115]. Beta carotene is a plant-derived carotenoid. It was extracted from skin sections 
adjacent to fatty tissue. The characteristic peaks of beta carotene at 1008, 1156 and 1515 
cm-1 are consistent with a previous study [116].  
 
 
Figure 2.6: Extracting melanin from a MM skin section. Raman image of melanin (d) 
are compared with bright field image (a) RCM image (b) and 
histopathology image (c). Basis spectra of melanin and beta carotene are 
shown on the right. Scale bar: 50 μm. 
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2.3.1.6 Miscellaneous 
In Raman imaging, water came from the saline used to keep the skin section moist. 
We found water plays an important role in fitting the broad Raman band at 1645 cm-1. 
Hemoglobin and calcium hydroxyapatite (CaH) were only detected in one skin section but 
were included in our library. Morphologies such as hair follicle (HF) and keratin pearl (KP) 
were also obtained. KP was extracted from SCC lesions with acceleration of keratinization. 
Figure 2.7 shows the basis spectra of these constituents. Although the spectra of HF and 
KP are similar, the difference spectrum suggested that the former contained cellular 
information (DNA backbone at 835 cm-1 and phosphodioxy group PO2
-1 at 1093 cm-1). 
Finally, we included a spectrum of fiber background generated from the Raman optical 
fiber probe. This component is used to fit the broad peak between 1000 – 1100 cm-1 in the 
in vivo data.  
 
Figure 2.7: Basis Raman spectra of water, calcium hydroxyapatite (CaH), hemoglobin 
(Hb), hair follicle (HF) and keratin pearl (KP) collected in situ are 
displayed. The difference spectrum between HF and KP is also shown. 
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2.3.2 Biophysical Modeling Results 
A total of fifteen candidate model components were derived. The basis spectra were 
peak normalized with a minimum value of 0 and maximum value of 1. Their collinearity 
coefficients are displayed in Table 2.1. Beta carotene and calcium hydroxyapatite are not 
shown because they have low collinearity (< 0.50) with other components. Several 
components have high collinearity, such as in situ keratin in epidermis, keratin pearl (KP), 
and hair follicle (HF), likely because keratin dominates their chemical composition. As a 
result, we selected only one model component to represent keratin. In addition, we 
observed high collinearity between cell cytoplasm (Cyt) and other protein-rich components 
(elastin (Ela), keratin, KP, and HF). These components share common features of many 
functional groups, such as C-C stretching around 939 cm-1, Amide III around 1270 cm-1, 
CH modes around 1454 cm-1 and amide I around 1660 cm-1. Considering that (1) cell 
cytoplasm has a much smaller Raman scattering cross-section and less quantity than 
keratin, and (2) the spectrum of keratin may contain some cell features due to their close 
proximity, we finally excluded cytoplasm from our model.  In addition, Raman spectrum 
of palmitic acid (PA) has a high degree of overlap with triolein (0.94) and ceramide (0.96), 
so PA was also excluded from the model. In total, we arrive at eight primary Raman active 
components: collagen, elastin, triolein, cell nucleus, keratin, ceramide, melanin and water 
(Figure 2.8). The peak positions of main Raman bands are displayed in Table 2.2.   
 
  
29 
 
Table 2.1: Collinearity measurement for candidate model componentsa. 
  Col Ela Ker KP HF Cyt Nuc Trio Cer PA Mel Hb Water 
(a) 
Col 1.00             
Ela 0.89 1.00            
Ker 0.88 0.93 1.00           
KP 0.86 0.94 0.97 1.00          
HF 0.77 0.90 0.94 0.95 1.00         
(b) 
Cyt 0.86 0.93 0.95 0.97 0.95 1.00        
Nuc 0.64 0.76 0.70 0.75 0.78 0.77 1.00       
(c) 
Trio 0.70 0.78 0.82 0.82 0.84 0.86 0.59 1.00      
Cer 0.56 0.62 0.66 0.66 0.70 0.72 0.44 0.85 1.00     
PA 0.65 0.75 0.79 0.79 0.82 0.83 0.51 0.94 0.96 1.00    
(d) Mel 0.47 0.58 0.56 0.61 0.56 0.57 0.48 0.39 0.33 0.42 1.00   
(e) 
Hb 0.64 0.73 0.68 0.72 0.67 0.69 0.61 0.41 0.34 0.44 0.78 1.00  
Water 0.56 0.58 0.58 0.65 0.57 0.62 0.48 0.33 0.20 0.29 0.55 0.60 1.00 
aComponents are sorted according to their major composition: (a) protein, (b) cell, (c) lipid, (d) pigment, (e) miscellaneous. 
Components include collagen (Col), elastin (Ela), keratin (Ker), keratin peal (KP), hair follicle (HF), cell cytoplasm (Cyt), cell nucleus 
(Nuc), triolein (Trio), ceramide (Cer), palmitic acid (PA), melanin (Mel), hemoglobin (Hb) and water. 
 
 
Figure 2.8: Basis spectra used in the biophysical model of skin. Model components 
include collagen (a), elastin (b), triolein (c), nucleus (d), keratin (e), 
ceramide (f), melanin (g), water (h).  
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Table 2.2: Peak positions of main Raman bands in the Raman active components.  
Raman peaks  
[cm-1] 
Band assignments  Components 
835 DNA backbone: O-P-O/ tyrosine nucleus 
855 CCH bending (aromatic) of protein elastin, keratin 
856 C-C vibration of the collagen backbone collagen 
937 C-C stretching of proline and valine and protein backbone keratin 
940 C-C stretching of protein backbone collagen, elastin 
1003 C-C vibration of phenyl ring 
collagen, elastin, 
keratin 
1063 C-C asymmetric skeletal stretching of lipids (trans-conformation);  ceramide 
1080 C-C skeletal stretching triolein 
1093 O-P-O symmetric stretching vibration of the DNA backbone nucleus 
1128 C-C symmetric skeletal stretching ceramide 
1248 Amide III (β-sheet and random coil conformations) collagen, elastin 
1254 β sheet/ thymine/ cytosine (DNA base/ DNA & RNA base) nucleus 
1269 Amide III (α-helix conformation), C-N stretching, N-H in-plane bending 
collagen, elastin, 
keratin 
1301 C-H modes (CH2 twisting and wagging) of lipids; CH2/CH3 bands triolein 
1336 desmosine/isodesmosine  elastin 
1337 adenine, guanine (DNA & RNA base) nucleus 
1378 linear stretching of the C-C bonds within the rings melanin 
1440 CH2/CH3 bands triolein, ceramide 
1450 C-H bending of proteins keratin 
1454 C-H stretching, C-H asymmetric deformation collagen, elastin 
1573 in-plane stretching of the aromatic rings melanin 
1645 O-H bending mode of liquid water water 
1653 C-O stretching model of amide I keratin 
1656 C-C lipids triolein 
1665 C-O amide I vibration collagen, elastin 
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Figure 2.9: Model fitting results for in vivo human skin spectra categorized as Normal, 
BCC, SCC, AK, PL and MM. Mean Raman tissue spectra (solid lines), 
model fits (dotted lines), residuals are plotted on the same scale. Fit 
coefficients in percentage are listed on the right. The arrow indicates the 
most characteristic changes for each lesion type.  
 
In an effort to validate that these eight components captured the primary skin 
constituents as measured on in vivo human skin cancers, we fit this linear component model 
to the clinical data set. We determined the relative contribution from the eight model 
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components of each of the pathology groups. Figure 2.9 shows the fitting result of the 
mean Raman spectra. Considering the order of magnitude of the residuals with respect to 
the bulk tissue spectra, most of the spectroscopic features are well represented. The fit 
coefficients across each model component are normalized to sum to 1.  
 The results illustrate key biophysical changes of skin with different tissue types. 
For instance, normal skin has an average of 41% triolein, 30% of dermal ECM (collagen 
and elastin), and minor contribution from nucleus, ceramide, melanin and water. However, 
the contribution of triolein drops significantly from normal skin (41%) to nonmelanoma 
skin cancer/precancer (BCC, SCC, AK) (28%, 32%, 32%) and to MM, PL (11%, 23%). As 
expected, melanin content is much higher in MM (29%) and PL (19%) compared to other 
tissue types (3 – 7%). In addition, keratin concentration is higher in SCC (11%) as 
compared to other tissue types (1 – 3%). 
2.4 DISCUSSION 
In this chapter, we establish a Raman “biophysical model”, an inverse model for 
determining biophysical skin components using in vivo Raman spectroscopy. We built a 
confocal Raman microscope to identify eight of the most relevant skin constituents 
contributing to the spectral differences among different skin malignancies.  
Our model components were found to be consistent with previous studies. Some 
were commonly used in skin and non-skin models. For instance, collagen and triolein are 
known to be important contributors to the Raman signal of breast, gastric, and artery tissues 
[97, 99, 100]. We demonstrated these two components also played an important role for 
fitting in vivo skin data. Other components were more specific to skin. For instance, 
Caspers et al. used ceramide to model epidermal lipid in human stratum corneum layer 
[117]. Silveira et al. included elastin to model skin dermal protein [65]. Keratin was 
important for in vivo skin to consider the impact of epidermis [101, 117] but not necessary 
for excisional skin fragments because the measurement was on the dermis side [65]. 
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Melanin was important only when pigmented lesions were considered, so it was used to 
model melanoma skin tissue [65].  
However, our model is different from previous biophysical Raman skin models in 
the following two aspects. First, we used skin constituents in their microenvironment as 
the basis spectra. Our results showed that it was possible to use a single morphologically 
derived basis spectrum rather than synthetic/purified chemicals. As demonstrated in the 
Results section, in situ skin constituents had substantial differences from their 
corresponding synthetic chemicals, even if their major chemical components were the 
same. Since in situ constituents are extracted from skin in their natural state, without any 
further processing, they can better represent the skin microenvironment that cannot be 
recapitulated in a synthetic environment. Second, our model was validated by a previous 
in vivo clinical screening study [67] acquired by a Raman optical fiber probe [106]. 
Currently, the only biophysical Raman skin cancer model was based on excised fragments 
of BCC and melanoma skin tissues [65]. We expanded upon this research to apply our 
model to in vivo skin spectra study and covered a wider range of nonmelanoma and 
melanoma skin cancers and precancers.  
While we found a total of 15 measurable Raman components in skin, we found the 
most consistent model outcomes were achieved when minimizing this number to only eight 
components. Our approach was to select only one Raman constituent to represent those in 
situ components that were chemically similar and with high collinearity. Similarly, Stone 
et al. demonstrated that including both amino acids and the proteins containing them in a 
linear model skewed the fit coefficients [96]. Our experience is that minimizing the number 
of protein components resulted in the most consistent fit coefficients.  
The biophysical changes of skin derived by our model follow known morphological 
and biochemical changes in skin malignancy. We observed that there is less triolein in skin 
cancer/pre-cancer lesions relative to the amount of triolein in normal skin. Triolein is a 
major form of triglyceride in human skin, which presents as subcutaneous fat and 
epidermal surface lipid. The apparent decrease in triolein as cancer progresses could be due 
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to: (1) the reduction of subcutaneous fat sampled by the probe, caused by the thickening 
epidermis during lesion formation; and/or (2) the reduction of membrane lipid synthesis 
induced by UV damage [34]. Because subcutaneous fat exists in a substantial amount and 
has large Raman scattering cross section [118] we believe (1) is the major reason. The 
thickening of epidermis originates from the progression of malignancy [119].  
While both melanoma and nonmelanoma skin cancers were included in this study, 
the direct comparison between BCC or SCC and MM is much less clinically relevant [120]. 
Thus, we compared nonmelanoma (BCC, SCC, AK) versus normal skin and MM versus 
PL separately. We observed that the amount of collagen was substantially lower in 
nonmelanoma skin cancer lesions as compared to normal skin. This could be explained by 
the breakdown of collagen in dermis due to the role metalloproteinases (MMP) play in 
degrading collagen and prohibiting procollagen biosynthesis [35]. The thickening of the 
epidermis also leads to reduced collagen signal collected by the probe. Furthermore, we 
observed the amount of elastin was higher in BCC lesions as compared to normal skin, 
potentially resulting from the existence of solar elastosis. Elastosis is characterized by the 
accumulation of disorganized elastic fibers in the dermis and commonly found in 
photoaging skin [36]. Finally, we found keratin was substantially higher in SCC compared 
to the other groups, which suggests massive keratinization disorders during SCC tumor 
progression [37].  
By visual inspection, the mean spectra of MM and PL appear very different than 
the mean spectra of other pathologies. The spectral flattening between 1500 and 1700 cm-
1 is caused by increased melanin and pigmentation, indicating Raman is sensitive to 
pigment-related variations. However, discriminating MM from PL remains the most 
challenging discrimination in skin cancer screening, resulting in high negative biopsy ratios 
clinically. In our study, we observed melanin content in MM is substantially higher as 
compared to PL, indicating massive melanocyte proliferation. The significantly lower level 
of triolein in MM than PL could be explained by both the reasons given above and by the 
strong absorption of melanin, which further reduced the signal sampled from subcutaneous 
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fat. In addition, collagen is substantially lower in MM than PL. This suggests that tumor 
formation is closely related to the changes in its stroma microenvironment in favor of its 
proliferation and eventual metastasis [37, 38]. Our model demonstrated that collagen, 
triolein, and melanin are the most important cancer identifiers for MM. Future work will 
explore the diagnostic potential of these biophysical parameters in discriminating skin 
cancers.   
We observed a higher fitting residual in MM than the other tissue types. The basic 
assumption of our linear fitting model is that the scattering properties of tissue do not 
significantly distort the Raman spectrum [107], but this assumption may not hold for 
melanin due to its strong absorption and scattering. Intrinsic Raman spectroscopy may help 
correct this distortion by relating the observed and intrinsic Raman spectra through diffuse 
reflectance using light transport model [121]. We will also explore nonlinear fitting models 
to improve the fitting, such as partial least-squares (PLS) and support vector machine 
(SVM). Other factors also contribute to the residuals in general. One factor is that the basis 
spectra and bulk tissue spectra were acquired from two independent Raman systems, which 
were composed of different detectors, lenses, beam splitters, etc. Spectral response 
calibration was used to match the spectral response of the two systems, but it could not 
completely eliminate the differences in the spectra measured by the two systems. Another 
factor is the signal generated by probe components, such as the fiber background, epoxy 
and sapphire [106].  
In general, we did not find site-specific constituents that are not covered by the 
current model, but the concentration of the 8 components may vary due to location. For 
example, when the measurement was taken on the scalp surround with dark hairs we would 
detect melanin signal. Future work will examine how sensitive our model is in picking up 
such information.  
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2.5 CONCLUSION 
In this chapter, we proposed the first Raman biophysical model that used in situ 
Raman active components as the building blocks, and applied to in vivo skin cancer 
screening data. Our results indicate that eight basis spectra derived from collagen, elastin, 
triolein, cell nucleus, keratin, ceramide, melanin, and water are the most relevant to 
describe the spectral features of human skin Raman data. In the next chapter we will 
evaluate the performance of this model in discriminating skin cancer pathologies within 
the context of ongoing clinical studies of Raman spectroscopy for skin cancer screening in 
our group. We envision our model being used with the Raman probe for analyzing 
individual lesions pointed out by patents or providers. We think it would be reasonable to 
scan the top ten concerning lesions on any patients without affecting the current patient 
flow in a physician’s office.  
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Chapter 3: Biophysical basis of in vivo skin cancer screening using 
Raman spectroscopy2  
3.1 INTRODUCTION 
This chapter aims to explore the diagnostic markers that Raman spectroscopy relies 
on for accurate in vivo melanoma detection.  
 Previous studies have shown that Raman spectroscopy is highly sensitive in 
differentiating malignant melanoma (MM, the deadliest version of skin cancer) from 
benign pigmented lesion (PL, frequently confused in the clinic with MM) [4, 67, 122]. Our 
group has demonstrated that MM (12 lesions) can be discriminated from PL (17 lesions) 
with 100% sensitivity and specificity by using a novel Raman probe-based system [94] and 
principal component analysis (PCA) with a logistic regression classifier [67]. Schleusener 
et al. discriminated MM (23 lesions) and PL (33 lesions) with a balanced accuracy of 91%  
using partial least squares discriminant analysis (PLS-DA) [123]. Lui et al. discriminated 
MM (44 lesions) from PL (286 lesions) with 90 - 99% sensitivity and 15% - 68% specificity 
[4] using principal component analysis with generalized discriminant analysis (PCA-
GDA). A follow up independent validation study from the same group showed consistent 
results for discriminating MM (53 lesions) from PL (336 lesions) [124]. Their research 
later led to the commercial launch of a clinical skin cancer detection device (Verisante 
Aura) in Canada [4].  
Raman spectroscopy also has been used to detect nonmelanoma skin cancer 
(NMSC), mainly basal cell carcinoma (BCC), squamous cell carcinoma (SCC) and actinic 
keratosis (AK, a precancerous state). Lieber et al. developed a portable confocal Raman 
system with a handheld probe, and achieved 100% sensitivity and 91% specificity in 
discriminating BCC, SCC and inflamed scar tissues from normal tissues (21 versus 21). 
 
2Portions of this chapter are adapted from X. Feng, A. J. Moy, H. T. Nguyen, Y. Zhang, J. Zhang, M. C. 
Fox, K. R. Sebastian, J. S. Reichenberg, M. K. Markey, and J. W. Tunnell, "Raman biophysical markers in 
skin cancer diagnosis," J Biomed Opt 23, 057002 (2018). 
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The spectral differences were extracted through the maximum representation and 
discrimination feature (MRDF) statistical method [120]. Silveira et al. discriminated BCC, 
SCC, and AK from non-tumorous tissue (44 versus 55) with approximately 91.9% 
accuracy by using a dispersive Raman system and PLS-DA [125]. Schleusener et al. 
discriminated BCC from normal skin (35 versus 104) and SCC from normal skin (22 versus 
104) based on PLS-DA with a balanced accuracy of 73% and 85%, respectively [123]. Lui 
et al. distinguished skin cancer and AK from benign lesions with 90 - 99% sensitivity and 
24% - 66% specificity based on PLS [4].  Despite these successes, these studies have 
employed statistical classifiers, sometimes called “black box” methods, to describe the 
spectral differences between pathologies. The challenge with these statistical algorithms 
lies in interpreting the biophysical basis for their discriminant ability. That is, they do not 
provide insights into the most relevant cancer biomarkers that Raman spectroscopy relies 
on to make an accurate diagnosis. Therefore, we aim to determine the biophysical basis of 
skin cancer detection based on Raman spectroscopy. This may enable the pathologist to 
interpret the spectral data in a familiar manner (such as a thickening epidermis, the change 
of collagen and lipid content, etc.) and guide a dermatologist in determining the most 
appropriate treatment.  
In Chapter 2, we proposed a Raman biophysical inverse model to derive the skin’s 
biochemical makeup from its Raman spectrum [126]. The model described the Raman 
spectra from in vivo human skin as a linear combination of eight Raman active skin 
constituents extracted from skin in situ, including collagen, elastin, keratin, triolein, 
ceramide, nucleus, melanin, and water. We have validated the model using previous in vivo 
human skin cancer screening data [126] and identified distinct biophysical changes 
between pathologies. However, we have not evaluated the diagnostic potential of those 
biophysical parameters in discriminating skin cancers. We also have not identified the 
important biophysical features used as diagnostic tools.    
In this chapter, we present a preliminary study of in vivo diagnosis of melanoma 
and NMSC on the biophysical basis. We demonstrated that the biophysical model captures 
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the diagnostic power of the previously used statistical classification model while also 
providing the skin’s biophysical composition. Our work demonstrates the ability of Raman 
spectroscopy in sensing the biochemical composition of skin cancers, thus allowing for 
better interpretation of the diagnostic results from a pathological basis.  
3.2 MATERIALS AND METHODS 
3.2.1 Clinical Instrument and Dataset 
The clinical skin cancer screening study [67] was conducted using a Raman optical 
fiber probe [106] integrated in an optical fiber probe-based system [94]. An 830nm 
wavelength excitation was used to minimize tissue autofluorescence. Collected signals 
entered a spectrograph and were imaged onto a camera. Integration time for each 
measurement was 3s. Spectral resolution of the probe-based system is around 10 cm-1. This 
study was approved by the Institutional Review Board at The University of Texas at Austin 
and The University of Texas MD Anderson Cancer Center (trial registration ID: NCT 
00476905). Informed consents were acquired from all patients prior to the study.  
In vivo Raman spectra were obtained from 65 patients diagnosed with basal cell 
carcinoma (BCC), squamous cell carcinoma (SCC), actinic keratosis (AK), dysplastic nevi 
(DN, a dysplastic form of PL), and malignant melanoma (MM). Details of the clinical data 
are provided in Table 3.1. In total there are 100 lesions and 99 adjacent normal tissues 
because one normal tissue was shared between two lesions. Fourteen out of 38 SCC lesions 
containing both SCC and AK were grouped into SCC. Multiple spectra were taken from 
each lesion by moving the probe to different locations to sample as much of the lesion as 
possible. Multiple spectra were also taken from the normal skin adjacent to each individual 
lesion. Although not verified by histopathology, normal skin was visually verified to be 
normal by an experienced dermatologist or physician assistant.  
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Table 3.1: Summary of clinical data. 
Lesion type # patients 
# lesions  
(# spectra) 
# adjacent normal tissues 
 (# spectra) 
MM 10 12 (33) 11 (23) 
DN 11 17 (37) 17 (33) 
BCC 14 19 (39) 19 (38) 
SCC 20 38 (81) 38 (76) 
AK 10 14 (30) 14 (28) 
Total 65 100 (220) 99 (198) 
 
Table 3.2: Patient age for MM and DN. 
MM patient # Age DN patient # Age 
1 70 1 75 
2 58 2 69 
3 81 3 31 
4 - 4 34 
5 69 5 29 
6 33 6 69 
7 68 7 34 
8 70 8 28 
9 60 9 35 
10 78 10 22 
  11 34 
Average age 65  42 
 
3.2.2 Data Preprocessing 
Spectra underwent wavenumber calibration, dark noise removal, cosmic ray 
removal, and smoothing, followed by a fifth-order polynomial fitting [103] to remove 
tissue fluorescence background. Spectral data were spectral response calibrated using a 
tungsten halogen lamp (LS-1-CAL, Ocean Optics). Spectral band between 800 and 900 
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cm-1 was excluded due to a strong broad fiber background peak around 800cm-1. A sharp 
room light peak at 1100 cm-1 was removed from five spectra from one MM patient.  
3.2.3 Diagnostic Algorithms 
3.2.3.1 Classification Tasks 
We used four classification tasks in this study: (1) MM versus DN; (2) MM, DN 
versus normal (Norm); (3) NMSC (BCC, SCC, AK) versus Norm; and (4) SCC, BCC 
versus AK. Diagnostic algorithms were implemented within MATLAB (version R2015a, 
MathWorks).  
We chose these four classification tasks not only to be consistent with our previous 
study, but also based on their clinical significance. Task (1) is significant because it directly 
affects the decision of a clinician to remove the lesion or continue to observe when facing 
a pigmented lesion of concern. Task (4) is significant because while a BCC or SCC will 
require surgical excision, it is often sufficient to treat an AK with cryotherapy or a topical 
chemotherapeutic agent. Both task (1) and (4) are highly related to reducing the number of 
unnecessary excisional skin biopsies. Although Task (2) and (3) are not currently clinically 
actionable, they are very relevant to the perspective of tumor margin detection. We used 
normal skin as a placeholder for these other diagnoses, with the hope that in the future we 
can perform the analysis on enough benign lesions to allow the device to distinguish these 
benign issues from cancer. 
3.2.3.2 Receiver Operating Characteristic (ROC) 
An ROC curve was used to determine a model’s performance in discriminating 
between two groups. An ROC curve is a graphical representation of the trade-off between 
sensitivity and specificity. Sensitivity is the ability of the model to correctly identify the 
positive group, whereas specificity is the ability of the model to correctly identify the 
negative group. For good discrimination, the ROC curve is predominately in the left and 
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top boundaries of the graph, while for poor discrimination, the ROC curve approaches the 
diagonal line drawn from the bottom-left to the top-right of the plot. ROC curves were 
calculated separately for PCA and biophysical model, and for each of the four classification 
tasks. 
By default, the ROC curves were calculated by treating each lesion as an 
experimental unit. The method is described elsewhere [29]: if one or more spectra from a 
site were classified as cancer, the site was classified as cancer. If all spectra from a site 
were classified as normal, the site was classified as normal. We used this conservative 
technique to approximate the dermatologist’s tendency to err on the side of caution. 
3.2.3.3 Statistical Model  
The statistical model (PCA) was adopted from our previous publication [67]. For 
each classification task, we limited the number of principal components (PCs) to 5, because 
the diagnostic improvements dropped significantly beyond 4 [67]. Firstly, we performed 
PCA for a given classification task and then generated all the possible combinations of 1, 
2, 3, 4, or 5 PCs from the first 15 PCs. Next, we selected one combination of PCs and built 
a logistic regression classifier. Specifically, for each PC-logistic regression analysis, a 
successive single lesion was left out for testing, with the remaining lesions being used for 
training. After the posterior probabilities of all lesions were calculated according to the 
leave-one-lesion-out cross validation protocol, an ROC curve was then calculated. Using 
this method, we generated different ROC curves for different combinations of PCs. The 
combination of PCs that yielded the largest area under the ROC curve (AUC) was selected 
for subsequent analyses.  
3.2.3.4 Biophysical Model 
In vivo Raman spectra were fit into the biophysical model with eight primary model 
components: collagen, elastin, triolein, nucleus, keratin, ceramide, melanin, and water, as 
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shown in Figure 3.1. Those components were collected from human skin in situ and were 
averaged over multiple patients.   
 
Figure 3.1: (a) Eight model components: (1) collagen, (2) elastin, (3) triolein, (4) 
nucleus, (5) keratin, (6) ceramide, (7) melanin, (8) water. Peak positions of 
the main Raman bands are labeled. (b) Fitting results for the average 
Raman spectra of normal tissue, BCC, SCC, AK, DN, and MM. Black 
solid lines: average Raman tissue spectra. Red dotted lines: model fits. 
Residuals are also plotted on the bottom. Images are adapted from 
Reference [126]. 
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The model components contain both biochemical and structural information. For 
instance, nucleus refers to the nuclear material in the cell. Collagen and elastin refer to 
dermal extracellular matrix. Keratin represents epidermal extracellular matrix. Triolein 
mainly represents subcutaneous fat. Peak positions of the main Raman bands and their 
physical origin are summarized in Table 2.2 [126-129]. The sub-bands (or sub-peaks) were 
not listed but also played a role in the fitting. The fit coefficients provide the relative 
concentration of those components and were used as the input variables of the discriminant 
analysis. Similar to PCA model, for each classification task, we generated all the possible 
combinations of 1, 2, 3, 4, or 5 components from the 8 primary model components and 
built logistic regression classifiers. We then selected the combination of model components 
that yielded the largest AUC. 
3.2.4 Comparison of Discriminative Capability between Statistical and Biophysical 
Models 
Statistical analysis was performed using an open-source package written in R 
software (version 3.3.3) [130]. The AUC of two paired ROC curves were compared using 
the bootstrap test, with a goal to determine if the biophysical model provides at least 
equivalent potential for classification compared to statistical model.  
3.2.5 Interpretation of Biophysical Model Result 
The fit coefficients of the 8 model components generated by the biophysical model 
were visualized using scatter plots. Each scatter point represents one spectrum. The error 
bar generated by the 95% CI are used to represent the variance of the fit coefficient. 
Unpaired Student’s t-test was employed, and the corresponding p values were labeled to 
compare if the fit coefficients have any statistically significant difference between 
pathologies.  
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3.3 RESULTS 
3.3.1 Statistical Model versus Biophysical Model 
In Table 3.3, the diagnostically relevant model components in statistical and 
biophysical models are displayed and the AUCs are compared. Figure 3.2 compares the 
corresponding ROC curves. The AUCs of the ROC curves of the two models are not 
statistically distinguishable for the classification tasks of MM versus DN, [MM, DN] 
versus Norm, and [BCC, SCC] versus AK. However, the AUC of the ROC of the 
biophysical model for [BCC, SCC, AK] versus Norm is statistically significantly better 
than the corresponding statistical model (p < 0.0001). Table 3.4 compares the specificities 
of the two models corresponding to sensitivities of 90% and 95%, respectively.  
Table 3.3: Comparison of diagnostic performance of statistical model and biophysical 
model. 
Classification 
tasks 
# lesion 
Diagnostically relevant components ROC AUC  
Statistical 
model 
Biophysical model 
Statistical 
model 
Biophysical 
model 
MM vs DN 12 vs 17 PC 3,4,5,8,9 
collagen, triolein, 
melanin 
1.00 0.99  
[MM, DN] vs 
Norm 
29 vs 28 PC 1,6,9 triolein, melanin 0.89 0.93 
[BCC, SCC, AK] 
vs Norm 
72 vs 64 PC 3,4,8,9 
collagen, triolein, elastin, 
nucleus, ceramide 
0.58  0.76  
[SCC, BCC] vs 
AK 
68 vs 55 PC 3,6,7,8 collagen, keratin, water 0.62  0.65  
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Figure 3.2: Comparison of ROC curves between statistical model (thin line) and 
biophysical model (thick line) for the 4 classification tasks: MM vs DN, 
MM, DN vs Norm (adjacent normal tissue), BCC, SCC, AK vs Norm, and 
BCC, SCC vs AK. The ROC curves are statistically compared, and the p 
values are labeled. p ＞ 0.05 indicates no significant difference between 
the two curves. 
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Table 3.4: Comparison of specificities derived from ROCs according to sensitivities of 
95% and 90%. 
Classification tasks 
Statistical model  Biophysical model 
Sensitivity  
(%) 
Specificity  
(%)  
 
Sensitivity  
(%) 
Specificity  
(%) 
MM vs. DN 95 100  95  94  
 90  100  90 94  
[MM, DN] vs. Norm 95  64   95  71  
 90  71    90  75  
[BCC, SCC, AK] vs. Norm 95 10  95 18 
 90 6  90 39 
[SCC, BCC] vs. AK 95  21   95 11  
 90  21   90  21  
 
3.3.2 Biophysical Basis of Classification Results 
3.3.2.1 Malignant Melanoma (MM) versus Dysplastic Nevi (DN) 
The biophysical model reveals the biomarkers responsible for the variances 
between pathologies. Major bands used for fitting and their physical origin was shown in 
Table 3.3 and reported in literature [126-129]. The fit coefficients of the eight model 
components in DN and MM are displayed in Figure 3.3. Statistical analysis indicates 
significant differences in collagen, elastin, triolein, nucleus, and melanin content between 
MM and DN. Collagen and triolein contributed greatly to the spectral variance between 
MM and DN. By using the fit coefficients of collagen and triolein, 29 out of 33 MM spectra 
and 35 out of 37 DN spectra are correctly classified (Figure 3.4).  
The best result was achieved by employing 3 components: collagen, triolein and 
melanin, resulting in 12 out of 12 MM lesions and 16 out of 17 DN lesions being correctly 
classified.  ROC AUC is 0.99, and specificity is 94% (90% – 95% sensitivity, Table 3.4). 
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Figure 3.3: Fit coefficients of the 8 model components computed from the biophysical 
model. Each point represents a spectrum data. Significance tests are 
conducted for the fit coefficients of DN norm (the adjacent normal tissue 
of DN) versus MM norm (the adjacent normal tissue of MM), DN versus 
MM, and [DN norm and MM norm] versus [DN and MM]. ** p ≤ 0.01, * 
p ≤ 0.05. 
3.3.2.2 Pigmented Lesions (MM, DN) versus Adjacent Normal Tissue 
Figure 3.3 shows that pigmented lesions and their adjacent normal tissue have 
significant differences in triolein, collagen, ceramide, keratin, and melanin content. Our 
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results show that triolein and melanin are the most relevant model components to 
discriminate MM and DN from adjacent normal skin. The ROC AUC is 0.93 (Table 3.3) 
for sensitivities from 95% to 90% and specificities of 71% to 75% (Table 3.4).  
 
Figure 3.4: Scatter plot drawn from triolein and collagen content. The solid logistic 
regression line separates MM from DN.  
3.3.2.4 Nonmelanoma Skin Cancers (BCC, SCC) versus AK 
Figure 3.5 shows significant differences in collagen, nucleus, keratin and water 
between SCC and AK, as well as significant differences in keratin and ceramide between 
BCC and AK. The fit coefficients of collagen, keratin and water discriminated BCC, SCC 
from AK with a ROC AUC of 0.65 (Table 3.3), and specificities range from 11% to 21% 
for sensitivities corresponding to 95% to 90% (Table 3.4). 
50 
 
 
Figure 3.5: Fit coefficients of the 8 model components computed from the biophysical 
model. Each point represents a spectrum data. Significance tests are 
conducted for the fit coefficients of adjacent normal tissue of BCC (BCC 
norm) versus BCC, the adjacent normal tissue of SCC (SCC norm) versus 
SCC, SCC vs AK, and BCC vs AK. ** p ≤ 0.01, * p ≤ 0.05. 
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3.4 DISCUSSION  
In our previous work [67], we demonstrated the capability of Raman spectroscopy 
in detecting skin cancers using a statistical model. Here we show that a biophysical model 
can achieve consistent diagnostic performance with the statistical model while 
simultaneously extracting the relevant biomarkers accounting for the diagnosis.  
Our model reveals a markedly different biochemical and structural composition 
between pathologies. First, the amount of triolein is significantly lower in all skin lesions 
than surrounding normal skin. Triolein mostly originates from adipose tissue in the 
subcutaneous layer, with a small contribution from epidermal surface lipids [113]. Triolein 
has a large Raman scattering cross-section, thus contributing greatly to normal skin spectra. 
The decrease of triolein in skin lesions does not necessarily indicate the actual amount of 
fat decreases in skin lesions, only that there is a decrease in the triolein sampled by the 
probe. One possible reason is epithelial thickening associated with dysplastic progression 
[131, 132]. An increased thickness of epidermis would mean the total volume of tissue 
sampled would include more epidermis and less adipose tissue, thereby decreasing the 
amount of Raman emission from deeper skin layers (adipose). Another possible reason for 
the decrease of triolein in pigmented lesions relative to the adjacent normal skin is that 
melanin strongly absorbs excitation laser power and therefore reduces the contribution of 
triolein in Raman signal.  
Next, we found that the collagen content is significantly lower in nonmelanoma 
skin cancers than their adjacent normal tissue and AK. For instance, collagen does not 
change significantly in the progression from normal to AK (benign), but it decreases 
significantly from AK to SCC (cancer). This trend of decreased collagen in cancer was also 
observed in previous biophysical models of ex vivo human skin fragments [65], urological 
tissue [96], gastric/esophagus tissue [97], and cervical tissue [133]. This may be partially 
explained by the thickening of the epithelium as mentioned above. Other reasons may 
include the release of metalloproteinases (MMP) by cancerous cells to degrade dermal 
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connective tissue [134, 135], and extracellular-degrading enzymes secreted from 
fibroblasts that damage the stroma [136].  
Discriminating MM from benign pigmented lesions (especially DN) usually leads 
to large negative biopsy ratio. Due to their highly similar appearance, the ratio of negative 
versus positive biopsies ranges from 22:1 to 59:1 for experienced versus new general 
practitioners [5]. Understanding the biophysical basis of melanoma skin cancer progression 
is essential to reduce large negative biopsy ratio and save considerable associated costs and 
efforts. In our study, we discovered that collagen and triolein are the two most important 
biomarkers to differentiate MM from DN, and NMSCs from normal tissue. Two previous 
ex vivo studies based on Raman biophysical models also showed collagen and triolein (or 
fat) had important roles in tissue Raman spectra. Bodanese et al. discovered the amount of 
collagen and fat extracted from tissue Raman spectra can classify BCC from normal skin 
with sensitivity and specificity of 95% and 83% [64]. Haka et al. found the fit coefficients 
of collagen and fat can distinguish cancerous breast tissues from normal and benign tissues 
with 94% sensitivity and 96% specificity [118]. 
Our results show that melanin is an important biomarker for classifying pigmented 
lesions from adjacent normal tissue, which is as expected because pigmented lesions 
typically contain more melanin than the surrounding normal skin. However, we also found 
melanin is not as relevant as collagen and triolein in differentiating MM from DN. In fact, 
melanomas do not always have more melanin than do benign pigmented lesions. The 
existence of amelanotic melanoma is a good example – we estimated zero melanin content 
for the one amelanotic melanoma lesion in our sample. Blue nevi, on the other hand, 
contain abundant pigment but are not cancer. Thus, more data from amelanotic melanomas 
is needed to clarify the role that melanin may play in differentiating MM and DN. 
We were best able to classify NMSCs from normal skin by employing a model that 
considered collagen, triolein, elastin, nucleus, and ceramide. To better understand the 
biophysical changes of each pathology, we examined the lesion-normal pairs for BCC and 
SCC separately. We found that melanin content is significantly lower in BCC than in 
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adjacent normal skin, likely because the invasion of basal cells takes over the space 
normally occupied by the melanocytes. Although not statistically significant, the amount 
of nucleus and elastin is larger in BCC compared to its adjacent normal skin, which may 
be explained by the proliferation of cancer cells and the enlargement of nuclei. Elastin 
content is also larger in BCC than adjacent normal, probably because of the existence of 
solar elastosis [137]. On the contrary, SCC appears to have a higher amount of keratin, 
ceramide, and water as compared to its adjacent normal skin. The increase of keratin may 
be attributed to large areas of keratinization in response to malignant epithelial cells [138]. 
Ceramide indicates abnormal epidermal surface lipid synthesis and thus is a key component 
to differentiate SCC from normal skin.  
AK is the most common precursor lesion of SCC among lightly pigmented 
individuals. Almost every SCC that arises on sun-damaged skin has evidence of AK in the 
epidermis, either directly contiguous with or adjacent to the neoplasm [139]. However, AK 
and SCC have a similar crusted appearance, making it difficult to differentiate by visual 
examination. We found the most important components to discriminate SCC from AK are 
collagen, keratin and water. AK is confined to foci within the epidermis, whereas SCC may 
further invade into dermis. Thus, SCC is expected to have a higher amount of keratin than 
AK. Nucleus content is lower in SCC than AK, likely because the prominent keratinization 
in SCC occupies the space of cells. We also observed a higher amount of water content in 
SCC than AK. High wavenumber Raman will be an ideal tool to study the significance of 
water in NMSC diagnosis.  
An interesting discovery is that the normal tissue adjacent to a DN has significantly 
more collagen than normal tissue adjacent to a MM (Figure 3.2). We were suspicious that 
the observed difference in collagen could be simply due to aging since the average age of 
the MM patients (N = 9) in our study was 65 years (one patients did not have age 
information on record), while the average age of the DN patients (N = 11) was 42 years 
(Table 3.2). To control for the effect of aging, we built a generalized linear mixed-effect 
model [140] using patient age and collagen as fixed effects predictors, and tissue type as 
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the response variable (0 = normal tissue adjacent to DN, 1 = normal tissue adjacent to MM). 
We also included a random-effects term for intercept grouped by patient to account for 
patient-specific variations. Our result shows that the p value of collagen is 0.041, indicating 
the amount of collagen is a significant predictor of tissue type, even after controlling for 
age. It is plausible that there is more collagen in normal skin adjacent to DN than in that 
adjacent to MM because melanoma growth is not only associated with malignant growth 
of cancer cells, but also changes in its stroma microenvironment to support metastasis 
[141]. Paidi et al. discovered that the use of Raman spectroscopy is feasible to detect 
changes in the stroma of the lung microenvironment in response to primary breast tumors 
[142]. Sahu et al. found that early malignancy-associated changes in normal contralateral 
sites of oral cancer may lead to anatomical variability and cause misclassification between 
contralateral and tumor [143]. Boppart et al. raised the question that molecular surgical 
margin may be a better way to define tumor boundary than the “gold standard” structural 
tumor margin [144].  Further studies are needed to study changes in normal stroma in 
response to dysplastic progression.  
One limitation of this study is that it simplifies the model to only eight Raman active 
components. Although originally we had 15 components, we narrowed down to 8 to avoid 
collinearity issues [126]. We found including multiple chemically similar components (e.g. 
various proteins) would result in fitting results with high variance. However, as there are 
far more molecules in skin, this method may underestimate the contribution of other 
molecules to the Raman signal. Another limitation is the limited sample size, which is also 
the main reason that we used leave-one-out cross validation to compute the ROC AUC. It 
is worth mentioning that this method comes with the risk of over-optimism. This may be 
the cause for the discrimination of MM from DN being better than that of (MM, DN) from 
normal (Figure 3.2). Alternative methods include (1) k-fold cross validation (such as k = 
10), and (2) bootstrapping [145]. The former utilizes 10% of the data as a test set, and the 
other 90% as the training set. Although it avoids the caveat of using single observation to 
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estimate the model performance in each split of the data, it requires a larger sample size. 
The latter approach may provide a better estimate of internal validity [146].  
3.5 CONCLUSION 
In this chapter, we have demonstrated that the biophysical model has consistent 
diagnostic capability as our previously published statistical model. By comparing with the 
statistical model, we have demonstrated that the biophysical model captures the spectral 
variances between skin pathologies in four distinct classification tasks. More importantly, 
the biophysical model captures the relevant biophysical changes accounting for the 
diagnosis. In particular, we found that collagen and triolein were the most important 
biomarkers in discriminating malignant melanoma from benign pigmented lesions, and 
nonmelanoma skin cancers and precancers from surround normal skin. Our work 
demonstrated that Raman spectroscopy has great potential in diagnosing skin cancer 
noninvasively while extracting the skin’s biophysical composition.  
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Chapter 4: Biophysical basis of ex vivo skin cancer surgical margin 
detection using Raman spectroscopy3 
4.1 INTRODUCTION 
Achieving adequate margins during tumor margin resection is critical to minimize 
the recurrence rate and maximize positive patient outcomes during skin cancer surgery. 
Previous studies have demonstrated Raman spectroscopy can accurately detect basal cell 
carcinoma (BCC) from surrounding normal tissue; however, the biophysical basis of the 
detection remained unclear. Therefore, the goal of this chapter is to explore the relevant 
Raman biomarkers to guide basal cell carcinoma margin resection.  
Nonmelanoma skin cancer is by far the most common malignancy worldwide. 
Among more than 5 million new cases diagnosed annually in the US, approximately 80% 
are BCC [147]. Currently, Mohs micrographic surgery (Mohs) is the most effective method 
for the treatment of BCC. The 5-year recurrence rate of Mohs (1 – 3% for primary BCC 
and 5 – 7% for recurrent BCC) is much lower than standard surgical excision (3 – 10% in 
primary BCC and >17% in recurrent BCC) [11]. Mohs involves iterative excision of 
surgical margins of each stage, followed by frozen section histopathology. If the 
histopathological diagnosis indicates tumor still exists, further tissue layers will be 
removed until the margins are clear.  
Although effective, Mohs has several limitations, including time, expense, training 
requirements and lab infrastructure. Most tumors require 1 to 3 stages (sometimes as many 
as 5 – 6) for complete removal, with patients waiting under local anesthesia between each 
stage [148]. The total time for Mohs surgery can be anywhere from one to five hours. 
Infrastructure requirements may also be limiting, including the building and maintenance 
of histology lab, staff training and physician training. As these requirements pose 
 
3Portions of this chapter are adapted from X. Feng, M. C. Fox, J. S. Reichenberg, F. C. Lopes, K. R. 
Sebastian, M. K. Markey, and J. W. Tunnell, "Biophysical basis of skin cancer margin assessment using 
Raman spectroscopy," Biomedical Optics Express 10, 104-118 (2019). 
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significant barriers to its use, Mohs is used in less than half (~40%) of cases, and less 
effective treatments such as standard surgical excision are more frequently employed 
[149]. Moreover, disparities in access to care, such as in among different geographic 
regions and racial and ethnic groups, leads to substantial underutilization of Mohs in 
underserved populations [149, 150]. Therefore, a critical unmet need exists for low-
infrastructure technologies that would enable general dermatologists to perform resections 
with high accuracy.  
Raman spectroscopy is a nondestructive and label-free optical technique, and has 
demonstrated great clinical merits for tumor margin assessment in numerous types of 
cancer, including skin [151], brain [152, 153], oral cavity [154, 155], breast [57, 156], and 
stomach [157]. Those studies either use fiber-optical Raman probe for single point 
sampling or Raman microscopy (also called Raman microspectroscopy) for optical 
imaging. One major advantage of Raman microscopy is that it has high resolution and 
sectioning comparable with that of conventional histology. Moreover, it provides an 
objective diagnosis with minimal tissue processing. Previous studies have demonstrated 
Raman microscopy can discriminate BCC from normal skin tissues with sensitivity of 90 
– 100% and specificity of 85 – 93%. Nijssen et al. was among the first to discriminate BCC 
from surrounding normal tissue using Raman spectroscopy and reached 100%/93% 
sensitivity/specificity (15 patients, 59 spectra) [158]. Lieber et al. developed an in vivo 
Raman microscopy and achieved 100%/91% sensitivity/specificity (19 patients, 42 
spectra) in classifying BCC and squamous cell carcinoma from paired normal skin tissues 
[120]. Larraona-Puy et al. demonstrated the ability of Raman microscopy in discriminating 
BCC from surrounding normal tissue with 90%/85% sensitivity/specificity (20 patients, 
329 spectra) [159]. Kong et al. combined Raman microscopy with autofluorescence 
imaging to increase acquisition speed and achieved 100% sensitivity and 92.9% specificity 
for discriminating BCC [151]. 
Prior studies mostly utilized statistical algorithms to extract the spectral differences 
between BCC and normal tissue, such as principal component analysis [151, 158], linear 
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discriminant analysis [160] and maximum representation and discrimination feature [120]. 
Although such methods provided high diagnostic accuracy, they did not elucidate the 
nature and biochemical processes responsible for the spectral differences. Understanding 
the biophysical basis of the discriminatory power of Raman spectroscopy would increase 
fundamental knowledge of cancer processes as well as lay the groundwork for improving 
the diagnostic performance of the technology [40]. Therefore, our aim in this study is to 
obtain biophysically relevant markers from Raman spectra of BCC and surrounding normal 
tissue, and then build diagnostic model to guide BCC tumor margin delineation.  
In Chapter 2, we proposed a biophysical human skin cancer model, an inverse 
model that infers the skin’s biochemical makeup from its Raman spectrum [161]. Different 
from previous studies that selected a number of Raman bands as “fingerprints” to 
discriminate between healthy skin and tumor regions [159, 162], our method is based on 
the fitting of pure spectral components. We validated the model using previous in vivo 
human skin cancer screening data [67], and demonstrated the feasibility of Raman 
spectroscopy to capture relevant biophysical changes accounting for the in vivo diagnosis 
[163]. Later, we presented a preliminary study of BCC tumor margin detection using the 
biophysical model based on a small dataset from 14 patients [164]. This study 
demonstrated the feasibility of detecting biophysical changes between BCC and five 
primary normal structures (epidermis, dermis, hair follicle, sebaceous gland and fat), but 
has several limitations: firstly, the number of patients is small; secondly, inflamed dermis 
was not included in the study, which may be confused with BCC in histopathological 
diagnosis [151, 159]; finally, a more comprehensive analysis is needed to link our 
biophysical approach with molecular vibrational approaches [128, 129].  
In this chapter, we demonstrate that Raman spectroscopy is highly sensitive in 
capturing the biochemical differences between BCC and surrounding normal skin 
structures. Based on these biochemical differences, we can develop diagnostic algorithms 
to accurately discriminate BCC in Mohs excisions, which supports the future development 
of intraoperative assessment of tumor margins.    
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4.2 MATERIALS AND METHODS 
4.2.1 Patients and Sample Preparation 
This study was approved by the Institutional Review Board (IRB) at The University 
of Texas at Austin and the Seton Healthcare Family. A total of 30 frozen tissue blocks were 
collected from 30 patients who had undergone Mohs at Austin Dermatologic Surgery 
Center. 18 samples were found to have both BCC tumors and surrounding normal tissue, 
and 12 samples contained only normal tissue. Before the Raman experiment, 20μm tissue 
sections were sliced from frozen tissue blocks at -22C and transferred onto low Raman 
background glass slides (MgF2 substrates). Serial sections were transferred onto 
microscope slides for hematoxylin and eosin (H&E) staining. The H&E technique stains 
cell nuclei in purple (hematoxylin), and intracellular or extracellular protein in red (eosin). 
Tissue structure identification and histopathological diagnosis were provided by a board-
certified dermatologist.  
4.2.2 Raman Imaging Experiment and Data Preprocessing 
Raman imaging was performed using a custom-built confocal Raman microscope. 
We used a longer wavelength laser (830nm) to minimize tissue autofluorescence. 
Reflectance confocal and bright-field images are also collected simultaneously. A detailed 
system description can be found elsewhere [161]. The power delivered to the sample was 
approximately 45mW. Raman images were collected from “tissue-level” regions varying 
from 60×60 μm2 to 100×100 μm2 (2μm steps, 2s per step). The “tissue-level” regions 
consist of ~10 – 100 cells, approximating the resolution of a dermatologist reading an H&E 
slide.    
Raw Raman spectra underwent wavenumber calibration, dark noise removal, 
cosmic ray removal, smoothing, and a fifth-order polynomial fitting [103] to remove tissue 
fluorescence background. Spectral response calibration was conducted using a tungsten 
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halogen lamp (LS-1-CAL, Ocean Optics, FL, USA). The effective spectral range was 800 
to 1790 cm-1. Data were normalized to the area under curve.  
4.2.3 Clustering Analysis 
Raman pseudo-color images were generated by k-means clustering. K-means is an 
unsupervised algorithm for cluster analysis and can easily handle large amounts of Raman 
spectroscopy data for cell [165] and tissue [158] imaging. The first 100 principal 
components accounting for 95% - 99% of the variation in the dataset served as input for 
K-means. The number of clusters was determined by visual comparison of the pseudo-
color image and histopathology. Each cluster was represented by a centroid Raman 
spectrum and assigned a different color. To eliminate spectral outliers, any spectrum that 
belonged to a cluster that was more than three times the standard deviation from the mean 
of that cluster was omitted [158]. We then annotated the centroid Raman spectrum of each 
cluster as either BCC or normal skin structures: inflamed dermis (Inf), epidermis (Epi), 
dermis (Der), hair follicle (HF), hair shaft (HS), sebaceous gland (SG), and fat. HS is a 
long filament in the center of the follicle extended above the surface of epidermis (also 
called hair). HF is the sheath of cells and connective tissue that surrounds the root of a hair. 
HF and HS were separated because they had heterogenous biochemical composition [160]. 
While muscle tissue can be present in Mohs sections and has been studied in other Raman 
studies [151, 162], it generally appears in a small minority of cases; thus, we have excluded 
it from this study.     
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4.2.4 Raman Biophysical Model 
A previously developed biophysical model [161] was used to extract the 
biochemical composition from the centroid Raman spectra of BCC and normal tissue 
structures. The model consists of seven Raman active components: collagen, elastin, 
triolein, keratin, nucleus, ceramide, and water, as shown in Fig. 1. Melanin was not 
included because melanin played a minor role in fitting the spectra of normal tissue and 
non-pigmented BCC. All the model components were extracted from human skin sections 
in situ and contained rich biochemical and structural information. For instance, collagen 
and elastin were the major constituents in dermal extracellular matrix, while keratin was 
rich in epidermal extracellular matrix. Nucleus represented the nuclear material in the cell. 
Ceramide was important constituent in epidermal lipid, while triolein existed in small 
amount in sebaceous lipid and large amount in subcutaneous fat.  
4.2.5 Model Fitting and Statistical Analysis 
Each centroid Raman spectrum was described as a linear combination of the model 
components according to a non-negative linear least-squares fitting criteria. The fit 
coefficients were then visualized using scatter plots. The variation of the fit coefficient is 
represented by the error bar generated by the 95% confidence interval. The fit coefficients 
of BCC and individual normal tissue structures were statistically compared. To account for 
dependencies in the data inherent from measuring multiple skin structures per patient, 
linear fixed-effects models were employed with the skin structures (epidermis, dermis, etc.) 
treated as a fixed effect and the patient treated as a random effect. The models were fitted 
using restricted maximum likelihood and p-values were derived from t-tests using 
Satterthwaite approximations [166, 167]. 
4.2.6 Diagnostic Algorithm 
A logistic regression classifier was built to discriminate BCC from normal tissue 
structures based on their fit coefficients. Leave-one-patient-out receiver operator 
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characteristic (ROC) analysis was used to determine the optimum number of input model 
components., i.e., the models were trained using a subset of 29 patients and tested on the 
remaining one patient. To avoid overfitting, the number of input model components was in 
all cases no more than 4. Leave-one-spectrum-out ROC analysis was also performed for 
inspection of the misclassified spectra. The area under the ROC curve (AUC) was 
calculated to measure the discriminatory power of the classification model. The 
combination of sensitivity and specificity with of greatest clinical value was obtained from 
the ROC curve. Sensitivity determines the ability of the model to correctly identify the 
positive group, whereas specificity is the ability of the model to correctly identify the 
negative group. Positive predictive value (PPV) and negative predictive value (NPV) were 
derived from the following equation. PPV is the probability that the positive group (BCC) 
identified by the model is truly positive. NPV is the probability that the negative group 
(normal tissue) identified by the model is truly negative.  
 
 
𝑃𝑃𝑉 =  
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑡𝑟𝑢𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑡𝑟𝑢𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠 + 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑓𝑎𝑙𝑠𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠
 
(4.1) 
   
 
𝑁𝑃𝑉 =  
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑡𝑟𝑢𝑒 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒𝑠
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑡𝑟𝑢𝑒 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒𝑠 + 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑓𝑎𝑙𝑠𝑒 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒𝑠
  
(4.2) 
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4.3 RESULTS  
4.3.1 Annotated Tissue Spectra Database 
In total, we obtained 223 centroid Raman spectra from 30 patients, including 50 
spectra from BCC, and 173 spectra from normal structures (including inflamed dermis (N 
= 19), epidermis (N = 26), dermis (N = 47), hair follicle (N = 31), hair shaft (N = 18), 
sebaceous gland (N = 22), and fat (N = 10)).  
Reflectance confocal images were also collected from each region. The images 
could also be stitched together to generate a larger field of view. Reflectance confocal 
images of various skin structures are displayed in Appendix B.  
Figure 4.1 shows a typical example of Raman experiment. Good visual 
correspondence was observed between Raman pseudo-color images and H&E images of 
the serial section. Figure 4.2 shows the mean Raman spectra of BCC and normal structures. 
The main differences between BCC and epidermis/hair follicle/inflamed dermis can be 
found at 1093, 1577, 1663 cm-1 (assigned to nucleus), while the main differences between 
dermis and BCC can be found at 856, 940, 1248 cm-1 (assigned to collagen).  
4.3.2 Biophysical Model Fitting Results 
Figure 4.3 shows the mean Raman spectra fit to the model components in Fig. 1. 
The fit coefficients of the model components computed from the biophysical model were 
visualized in Figure 4.4. Statistical significance for BCC versus inflamed dermis, BCC 
versus epidermis, BCC versus dermis, and BCC versus hair follicle was demonstrated in 
Figure 4.4. A complete list of statistical comparison between BCC and individual normal 
structures was displayed in Table 4.1.  
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Figure 4.1: Raman experiment on a typical skin tissue section. (a) H&E image shows 
six measured regions of 100×100 μm2, being represented as empty 
squares. Scale bar: 500 μm. (b) H&E image of the serial section. (c) 
Bright-field image. (d) Reflectance confocal images. (e) Raman pseudo-
color image generated by k-means. Region 1 and 2 contains BCC (yellow) 
and dermis (blue), region 3 contains sebaceous gland (yellow) and MgF2 
substrate (blue), region 4 contains hair shaft (yellow) and hair follicle 
(blue), region 5 contains inflamed dermis (yellow) and dermis (blue), and 
region 6 contains epidermis (yellow) and MgF2 substrate (blue).  
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Figure 4.2: Mean Raman spectra ± SD of all individual tissue structures, including 
BCC, Inf (inflamed dermis), Epi (epidermis), Der (dermis), HF (hair 
follicle), HS (hair shaft), SG (sebaceous gland) and fat. (b) Spectral 
differences of mean spectra of BCC minus Epi, BCC minus HF, and BCC 
minus Inf are compared with the basis spectrum of nucleus. (c) Spectral 
difference of mean spectra of dermis minus BCC is compared with the 
basis spectrum of collagen. Peak positions of the main Raman bands are 
labeled.  
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Figure 4.3: Mean Raman spectra of BCC, Inf (inflamed dermis), Epi (epidermis), Der 
(dermis), HF (hair follicle), HS (hair shaft), SG (sebaceous gland) and fat 
fit to the model components in Fig. 1. Black solid lines: mean tissue 
spectra. Red dotted lines: model fits. Residuals are also plotted on the 
bottom.  
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Figure 4.4: Fit coefficients of the biophysical markers for BCC (N = 50), Inf 
(inflamed dermis, N = 19), Epi (epidermis, N = 26), Der (dermis, N = 47), 
HF (hair follicle, N = 31), HS (hair shaft, N = 18), SG (sebaceous gland, N 
= 22) and fat (N = 10). Each point represents a spectrum data. Statistical 
significance of BCC versus Inf, BCC versus Epi, BCC versus Der, and 
BCC versus HF are labeled. *p≤0.05, **p≤0.01. 
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Table 4.1: Statistical comparison between BCC and individual normal structures (*p≤
0.05, **p≤0.01). 
  Collagen Elastin Triolein Nucleus Keratin Ceramide Water 
 
 
 
BCC vs. 
Inflammation **   ** **   
Epidermis  *  ** **   
Dermis ** * * ** ** **  
Hair follicle    ** **  ** 
Hair shaft   ** **  **  
Sebaceous 
gland 
 ** ** ** ** ** ** 
Fat  ** ** ** **  * 
 
4.3.3 Discrimination between BCC and Normal Tissue Structures 
The optimum results to classify BCC from all normal structures were reached by 
using the fit coefficient of nucleus alone, leading to an AUC of 0.94 for leave-one-patient-
out ROC analysis, and 0.97 for leave-one-spectrum-out ROC analysis (Figure 4.5). 
Additional inclusion of keratin, triolein, and collagen in the classification model did not 
further improve the diagnostic performance (Table 4.2). A summary of misclassifications 
is displayed in Table 4.3. One may see that hair follicle and epidermis are more commonly 
misclassified as BCC compared to other normal structures. The discrimination threshold is 
chosen to prioritize either high sensitivity or high specificity, or a balanced combination of 
sensitivity and specificity (both ≥90%). By prioritizing high sensitivity, classification 
result achieved 100% sensitivity, 84% specificity, 65% PPV, and 100% NPV; while by 
prioritizing high specificity, classification result reached 52% sensitivity, 99% specificity, 
93% PPV, and 88% NPV.  
 
69 
 
 
Figure 4.5: ROC analysis for classifying BCC from all normal structures.  Black 
thick line: leave-one-spectrum-out ROC curve. Blue thin line: leave-one-
patient-out ROC curve.  
Table 4.2: Discriminating between BCC and all normal structures using optimum 
combination of components. 
# components Optimum combinations 
Leave-one-
patient-out 
ROC AUC 
Leave-one-
spectrum-out 
ROC AUC 
1 [nucleus] 0.94 0.97 
2 [nucleus, keratin] 
0.94 0.97 
[nucleus, triolein] 
[nucleus, collagen] 
3 nucleus, triolein, keratin] 
0.94 0.97 [nucleus, triolein, collagen] 
4 [nucleus, keratin, triolein, 
collagen] 
0.93 0.96 
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Table 4.3: Summary of misclassifications by prioritizing high sensitivity or specificity. 
 
 Sensitivity/ 
Specificity 
(%) 
PPV/ 
NPV 
(%) 
BCC 
Normal tissue structures 
 
Inf Epi Der HF HS SG Fat 
Prioritizing 
high 
sensitivity 
 
100/84 65/100 0/50 3/19 6/26 0/47 15/31 2/18 1/22 0/10 
Prioritizing 
high 
specificity 
 
52/99 93/88 24/50 1/19 1/26 0/47 0/31 0/18 0/22 0/10 
Balanced 
sensitivity 
and 
specificity 
 
90/92 76/97 5/50 2/19 5/26 0/47 6/31 1/18 0/22 0/10 
 
Figure 4.6 represents separating BCC from different categories of normal 
structures using the fit coefficients of two primary model components. Figure 4.6(a) shows 
that epidermis and hair follicle have the largest overlap with BCC compared to other 
normal structures. The overlap occurs when epidermis and hair follicle have comparable 
level of keratin and nucleus content as BCC. Figure 4.6(b) shows that fat and sebaceous 
gland can be easily separated from BCC because they have distinct nucleus and lipid 
content. Figure 4.6(c) (d) demonstrate inflamed dermis/dermis can also be separated from 
BCC using their distinct differences in nucleus and collagen.  
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Figure 4.6: Scatter plots demonstrates the performance of two primary model 
components in discriminating BCC from normal structures. (a) Nucleus 
and keratin content of BCC, epidermis and HF. (b) Nucleus and triolein 
content of BCC, fat and SG. (c) Nucleus and ceramide content of BCC 
and inflamed dermis. (d) Nucleus and collagen content of BCC and 
dermis. Red dots: BCC. Black crosses: normal tissue structures. Each 
point represents a spectrum data. The black line is the decision line drawn 
by logistic regression.  
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4.4 DISCUSSION AND CONCLUSION 
In this chapter, we evaluated the accuracy of Raman to discriminate between BCC 
and normal skin structures in excised Mohs skin sections. In contrast to previous studies, 
our discriminatory model was built upon the biochemical differences of Raman active 
components extracted from a previously developed model [161]. 
Our results show markedly different biochemical and structural compositions 
between BCC and normal tissue (Figure 4.4 and Table 4.1). One important finding is that 
the spectra of BCC has statistically significantly larger contribution of nucleus material 
compared to normal tissue structures, which is consistent with previous Raman studies 
[158, 159, 168]. As seen in Figure 4.2(b), mean BCC spectra have stronger contribution 
from 1093, 1577 and 1663 cm-1 assigned to nucleus compared to epidermis, hair follicle 
and inflamed dermis. This is also consistent with the H&E image in Figure 4.1(b), where 
there are smaller amounts of cytoplasm and higher density of cells present in the BCC 
tumor. Other studies have pointed out similar or increased nucleic contributions in inflamed 
regions according to the presence of specific Raman bands [151, 162].  
Another important finding is that BCC has significantly larger contribution from 
keratin compared to inflamed/normal dermis, and lower contribution from keratin than 
epidermis and HF. Keratin is a fibrous structural protein produced by keratinocytes and is 
abundant in normal epidermis. Keratinocytes are the predominant cells originating in the 
basal layer between epidermis and dermis, which then move towards the skin surface in a 
process of maturation and differentiation. The outermost skin layer, stratum corneum, 
consists about 80% of keratin in dry weight [128]. HF is also rich in keratin. The epithelium 
of HF forms a cylinder with different concentric layers, including the inner and outer root 
sheath, with each one expressing a distinct pattern of keratin [169]. Because keratin 
expression is closely related to differentiation of tumors, it plays a significant role in 
identifying the origin of BCC. Several studies have discovered that BCC may arise from 
germinative cells within the basal layer of epidermis or follicular structures [170, 171]. 
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Furthermore, BCC has significantly smaller amounts of collagen and elastin 
compared to dermis. The difference spectra in Figure 4.2(c) shows that BCC spectra have 
weaker contribution from 856, 940, 1248 cm-1 assigned to the vibrational modes of 
collagen type I and elastin. This is likely the result of the epidermal origin of the BCC, high 
in cellular content and low in connective tissue. We also found collagen in inflamed dermis 
is higher than BCC, but lower than normal dermis. This confirms the observation of an 
early study that a dense inflammatory infiltrate appears to have less collagen than normal 
dermis [158].  
Finally, BCC has significantly larger amount of triolein and ceramide compared to 
dermis, and larger amount of triolein compared to epidermis. The difference spectrum of 
BCC and dermis also shows higher contribution at 1080, 1128, 1440 cm-1 associated with 
lipids. A previous biophysical model built upon nonmelanoma skin cancer found an 
increased contribution of triolein to BCC spectra [65]. Another biophysical model also 
found an increase in triolein in urological carcinoma lesions [96]. Those studies suggested 
that maintaining sufficient lipid levels may be necessary to sustain fast tumor growth.   
Some normal structures have high biochemical similarity. For instance, the 
biochemical compositions of epidermis and HF are highly similar, which agrees with the 
fact that HF is an invagination of normal dermis [160]. As a result, a previous study 
grouped epidermis and HF together for clustering analysis [151]. The biochemical 
composition of HS may resemble either HF or SG. This is because HS consists of 
terminally differentiated keratinocytes that are produced by HF [169], but it is sometimes 
coated by the sebum secreted by SG [172]. This also explains why the fit coefficients of 
HS have larger variation compared to the other components. Fat and SG both have low 
nucleus and high triolein content, so they can be easily discriminated from BCC (Figure 
4.6(b)). 
We evaluated the diagnostic performance by prioritizing either high sensitivity or 
high specificity (Table 4.3). Achieving high specificity is clinically significant in tissue-
conserving surgeries such as Mohs, when preserving normal tissue is a critical concern. 
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Appropriate use criteria of Mohs include tumor location (such as “mask areas” of face), 
size, and patient type [173]. On the other hand, achieving high sensitivity is more clinically 
significant when the primary goal is to capture the entire margin based on aggressive 
growth histology rather than preserving normal tissue.  
By prioritizing high sensitivity, we achieved 100% sensitivity and 84% specificity 
in discriminating BCC from all normal tissue structures. Our results show that that nucleus 
accounts for most of the discriminant ability. By using the fit coefficient of nucleus alone, 
100% of the spectra annotated as dermis (40/40) and fat (10/10) were correctly classified. 
Most of the spectra annotated as SG (95%, 21/22) and HS (89%, 16/18) were also correctly 
classified. The misclassification in these latter two categories may be due to unknown 
tissue structures grouped as the same cluster as SG or HS, leading to high fitting error. On 
the contrary, HF, epidermis and inflamed dermis were the normal structures that were more 
easily misclassified as BCC. 16 out of 31 spectra annotated as HF were correctly classified 
(52%), 20 out of 26 spectra annotated as epidermis were correctly classified (77%), and 16 
out of 19 spectra annotated as inflamed dermis were correctly classified (84%). 
HF and epidermis were most easily misclassified as BCC. Figure 4.6(a) 
demonstrates that those misclassifications occur due to high nucleus content in some of HF 
and epidermis. The main reason is that HF may have abundant basal cells in inner and outer 
root sheath layer, whereas epidermis is rich in basal keratinocyte stem cells in stratum 
basale layer and polyhedral keratinocytes in stratum spinosum layer. About 16% of 
inflamed dermis was also misclassified as BCC. Corresponding with the H&E images 
indicated that inflamed dermis regions have higher number of nucleus than normal dermis, 
so their spectra were more similar to BCC than normal dermis.   
By prioritizing high specificity, we achieved 99% specificity, 52% sensitivity and 
93% PPV. High specificity indicates a region has high risk, so a dermatologist could 
remove more tissue from the corresponding region with high confidence of it being tumor 
[174]. In a Mohs guidance setting, this approach could reduce the number of skin samples 
processed for histopathology. The dermatologist would still make a histopathological 
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diagnosis on the final stage to ensure all the tumors are entirely removed; thus, one may be 
able to tolerate lower sensitivity. Ultimately, this system would need to be tested in an 
intraoperative setting to determine its impact on reducing the number of tissue samples 
needing histology processing. Our results showed 24 out of 50 spectra annotated as BCC 
were misclassified as normal structures. All the spectra annotated as dermis, HF, HS, SG 
and fat were classified correctly. Most of the spectra annotated as inflamed dermis (95%, 
18/19) and epidermis (96%, 25/26) were correctly classified.  
Although we have demonstrated Raman microscopy is highly accurate in 
evaluating skin tumor surgical margin, one major limitation is lengthy acquisition time. To 
raster scan a tissue 1mm2 in size, it would take around 10 – 20 hours, making it unpractical 
for intraoperative use. To overcome this limitation, several wide-field imaging techniques 
could be employed. Kong et al. integrated Raman microscopy with tissue autofluorescence 
imaging and achieved one or two orders of magnitude faster speed [151]. Karen et al. 
developed fluorescence confocal mosaicking microscopy and proved its potential for rapid 
assessment of BCC margins during Mohs [175]. Flores et al used fluorescence confocal 
mosaicking microscopy to enable rapid detection of residual tumor directly in the surgical 
wounds on patients [18]. Further directions for this work include speeding up Raman 
acquisition without losing molecular specificity, and combining Raman spectroscopy with 
wide-field imaging technique for fast intraoperative surgical guidance.  
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Chapter 5: Superpixel Raman spectroscopy for rapid skin cancer 
surgical margin assessment  
5.1 BACKGROUND 
Although confocal Raman microscope has demonstrated high accuracy in detecting 
tumor margin, one major challenge is the acquisition speed is slow. A good signal-to-noise 
ratio spectrum typically takes 1 second in tissue; thus, to scan a centimeter scale sample 
would take hours or even days. This makes histopathology impractical for use during 
surgery for most cancer types. As a result, this chapter centers on expediting the acquisition 
speed of Raman spectroscopy for cancer margin detection.  
5.2 BASIC PRINCIPLE OF SUPERPIXEL ACQUISITION 
We describe a superpixel acquisition method for rapid human skin cancer margin 
assessment. Figure 5.1 demonstrates its basic principle. While sparse point-by-point 
scanning requires 1s for each pixel, superpixel acquisition only takes 1s for the whole area, 
thus substantially speeding up the acquisition. When the laser spot size is 1μm and 
superpixel size is 100μm, speed gain would be 10,000x.  
 
 
Figure 5.1: Comparison between sparse point-by-point scanning and superpixel 
imaging.  
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As seen in Figure 5.2, a tradeoff exists between speed up factor and spatial 
resolution. Our preliminary superpixel acquisition data were obtained based on 100μm 
superpixel size, because reasonable resections are a least a few hundreds of microns. In the 
future, we will perform experiment on different superpixel sizes to determine the optimum 
size.  
 
Figure 5.2: Tradeoff between superpixel size and speed up factor. Here show three 
different sizes: 25μm, 50μm, and 100μm. 
5.3 PRELIMINARY RESULTS OF SUPERPIXEL ACQUISITION 
We have obtained some preliminary results on both tissue-simulating phantom and 
human skin samples. Figure 5.3(a) shows an example experiment on a basal cell carcinoma 
(BCC) section. We sampled on both BCC and normal tissue structures (epidermis, dermis, 
inflamed dermis, hair follicle, hair shaft, sebaceous gland, and fat). In total, we collected 
data from 154 sites from 10 samples in 8 patients undergoing Mohs surgery. We then 
applied the biophysical inverse model to the average tissue spectra and extracted the 
concentration of the biomarkers. Finally, we used the diagnostic model described in 
Chapter 4 to classify BCC from normal tissue structures. Our initial results demonstrated 
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that the optimum classification result can be achieved by combining the biochemical 
changes of nucleus, collagen, keratin, and ceramide. Figure 5.3(b) showed that superpixel 
acquisition has consistent diagnostic performance as compared to point-by-point scanning.  
 
Figure 5.3: (a) Example of superpixel experiment on a basal cell carcinoma (BCC) 
section. From each superpixel (100×100μm2), we generated one average 
Raman spectrum. The reflectance confocal images and average tissue 
spectra are shown on the right. The white squares label the location of the 
superpixel (100×100μm2). (b) ROC curves of superpixel acquisition 
versus point-by-point scanning.   
5.4 SUPERPIXEL IMAGING 
5.4.1 Instrumentation 
After demonstrating the capability of superpixel acquisition, our next step is to 
perform superpixel imaging on a large field of view (e.g. 1×1mm2). Our previous system 
only allows for scanning a maximum of 300×300μm2 by steering the laser beam using 2D 
galvanometer mirrors. Therefore, we added a 2D motorized translation stage to translate 
the sample. Figure 5.4 compares the optical system before and after adaption. We changed 
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the system from inverted objective setup to upright setup due to the mechanical restraint of 
the motorized stages. However, in our future work we will replace it with a high-speed 
linear stage (e.g. HLD117, Prior Scientific [33]), which has a fast translation speed, and 
can be easily mounted on a commercial microscope base. Another system upgrade in the 
future is adding autofocusing in the z axis [33]. For the preliminary study, we placed a 
quartz slide on the top of the sample to improve surface flatness. However, the image blurs 
when the stage moves a few millimeters. An autofocusing algorithm would keep the sample 
within focus at all times, enabling a larger scan area. Appendix D Table D.1 summarizes 
the key components of this system. 
 
Figure 5.4: (a) Previous system (inverted objective setup, the tissue is stationary). (b) 
Current system (upright objective setup, the tissue is mounted on a 2D 
motorized translation stage). (b) is adapted from (a) for superpixel 
imaging.  
 
Figure 5.5 displays the LabVIEW program for automated superpixel imaging. The 
user records the X and Y value of the initial position, defines the size of the superpixel (25, 
50, 75, or 100 μm), the number of steps, and the integration time. Once click “Run”, the 
galvanometer mirrors will scan continuously to generate the superpixel, and the reflectance 
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confocal image will be displayed and saved in real time. Meanwhile, the motorized stage 
will translate the sample in 2D, and the CCD camera will capture one spectrum for each 
step. To repeat the measurement for the same region, the user only needs to move the 
motorized stage back to its original X and Y position.    
  
 
Figure 5.5: LabVIEW program for automated superpixel imaging.   
5.4.2 experiment 
In Figure 5.6, we imaged two Mohs surgical specimens, one positive margin and 
one negative margin. The positive margin contains basal cell carcinoma and normal tissue, 
and the negative margin contains only normal tissue. We tested three superpixel sizes 
within the same 1×1mm2 area. A prior classification model was applied to each superpixel, 
labeling each superpixel as positive or negative. The results showed Raman correctly 
classified most of the positive and negative margins for the 100 μm, 50 μm and 25 μm 
superpixel images. In the future, we will collect more superpixel images, and correlate each 
pixel with the ground truth diagnosis. We will then optimize the classification model to 
improve the diagnostic performance.  
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Figure 5.6: An example superpixel imaging experiment. (a) Positive margin. (b) 
Negative margin. Three superpixel sizes were tested: 100μm, 50μm, and 
25μm. The classification maps shown here targeted at high specificity. 
Yellow: positive. Blue: negative. Scale bar: 200μm. 
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Chapter 6: Conclusion  
The goal of this dissertation is to explore the biophysical origin of skin cancer 
detection using Raman spectroscopy. We built a mathematical inverse model (Chapter 2) 
and demonstrated that Raman spectroscopy is a promising tool for early cancer screening 
(Chapter 3), and surgical guidance of tumor margin delineation (Chapter 4 & 5).  
Our previous clinical study showed that Raman spectroscopy has high accuracy in 
detecting malignant melanoma, the deadliest version of skin cancer. However, the 
statistical method we used for classification does not reveal the key diagnostic markers that 
Raman spectroscopy relies on to make an accurate diagnosis. Therefore, we built a 
biophysical inverse Raman model using eight primary Raman active biomarkers, including 
proteins (collagen, elastin, keratin), lipids (ceramide, triolein), cell nucleus, pigment 
(melanin), and water. We found those biomarkers are the most relevant in describing the 
spectral differences between normal skin and various diseased states.  
For in vivo melanoma detection, we concluded that collagen and triolein are the two 
primary diagnostic markers. An interesting result we found is that the decrease of triolein 
(or subcutaneous fat) signal in melanoma is partially due to the epidermal thickening effect. 
Thickened epithelium prevents light from entering deeper layer of the skin, leading to a 
substantial decrease of Raman emission from fat. The biophysical changes we observed is 
based on our non-confocal probe, which has a relatively large tissue probing volume and 
deep tissue interrogation. It is worth noticing that the biophysical changes detected by 
Raman spectroscopy may vary depending on the probe design, as discussed by the Huang 
group [176]; however, the eight Raman active components will not change with the probe 
design. To further improve our study, we can include patient information in the diagnostic 
model (gender, race, family history, etc.), and confirm the biophysical changes (such as the 
epidermal thickening process) from histopathology and other optical imaging modalities 
(such as optical coherence tomography).  
For ex vivo surgical margin detection, our results showed that Raman spectroscopy 
is highly accurate in discriminating basal cell carcinoma. Significant differences were 
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observed for nucleus, keratin, collagen, triolein, and ceramide content between basal cell 
carcinoma and surrounding normal tissue structures. Particularly, nucleus accounted for 
most of the discriminant power. We also highlighted a few classification tasks that the 
dermatologists are mostly interested, such as basal cell carcinoma versus epidermis and 
hair follicle, and basal cell carcinoma versus normal and inflamed dermis. Our results 
indicated that epidermis and hair follicle are mostly easily misclassified as basal cell 
carcinoma, especially in regions where the nucleus content is high. Besides, inflamed 
dermis has an increased amount of nucleus, and decreased amount of collagen compared 
to normal dermis. These results are consistent with standard histopathological diagnosis.  
Finally, we described a superpixel acquisition approach for rapid human skin 
cancer surgical margin assessment. We envision this approach being used to develop an 
accurate, inexpensive, and efficient cancer imaging device, to aid Mohs surgeons and 
general practitioners in skin margin assessment during surgery.   
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Appendices 
APPENDIX A: SYSTEM CHARACTERIZATION 
A.1 Confocal Raman Microscope 
Lateral, axial, and spectral resolution of the confocal Raman microscope is 1μm, 
8μm, 8 cm-1, respectively. System was characterized using the method described in 
Reference [177].   
 
Figure A.1: Lateral, axial, and spectral resolution of the confocal Raman microscope.  
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A.2 Reflectance Confocal Microscope (RCM) 
The maximum field of view of reflectance confocal microscope (RCM) is 300μm 
in diameter, as shown in Figure A.2. The field of view is limited by the aperture of the 
scanning lens. Currently, two achromatic doublets act as the scanning lens and tube lens to 
conjugate the 2D galvanometer mirrors to the back aperture of the microscope objective. 
However, a doublet has limited aperture and severe optical aberrations on the periphery of 
the image. Therefore, only the central 200×200 μm2 region is used. In our future work, we 
should replace the doublet with a scanning lens or F-theta lens.  
 
Figure A.2: Characterizing the field of view of RCM image using an USAF 1951 
resolution target. A neural density filter with OD = 2.0 was used to 
attenuate the laser power to ~1% to prevent damage to the coating of the 
resolution target. The voltage of the current preamplifier was increased 
from 0.48V to 0.65V. Group 4 element 2 corresponds to 17.96 line pairs 
per mm (arrow). (a) +/- 3.0V input voltage. (b) +/- 1.0V input voltage. (b) 
is a 100×100μm2 superpixel.  
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The lateral resolution of RCM is better than 1μm, as seen from Figure A.3. 
Individual polystyrene beads can be clearly resolved.    
 
Figure A.3: Characterizing the lateral resolution of RCM using 1μm polystyrene 
beads.  
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APPENDIX B: RCM IMAGE OF SKIN 
B.1 RCM Image of Tissue Sections 
 
Figure B.1: RCM images of various tissue structures on Mohs skin sections. Each 
image has a size of 200×200μm2. 
 
 
Figure B.2: Left: RCM image of a basal cell carcinoma (BCC) section. Right: H&E 
stained image of the serial section. BCC tumor is highlighted in red in 
both images. The RCM images were stitched together using Microsoft 
Image Composite Editor (ICE).  
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Figure B.3: Left: RCM image of a normal section. Right: H&E stained image of the 
serial section. Two hair follicles can be clearly identified from the image 
(yellow arrows).  
B.2 RCM Image of Unsectioned Tissue Blocks 
RCM images can be obtained directly from the unsectioned tissue blocks. This 
indicates that diagnosis can be obtained directly by analyzing the surface of tissue blocks 
removed during surgery without cutting thin sections [151]. In Figure B.4, stratum 
corneum and dermis can be clearly identified from a skin tissue block. The RCM image of 
stratum corneum matches with a previous study [42]. 
 
Figure B.4: RCM image of a skin tissue block. (a) (b) Stratum corneum side. (c) (d) 
Dermal side. 
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APPENDIX C: RCM VS TWO-PHOTON-EXCITED FLUORESCENCE IMAGE  
High correlation is found between RCM image and two-photon-excited 
fluorescence (TPEF) image, as shown in Figure B.5.  
 
Figure B.5: Comparison between RCM and TPEF image. (a) TPEF image of a human 
skin section. (b) Zoom-in. Excitation wavelength: 820nm. Objective lens 
20x. (c) Bright-field image. (d) RCM image. Comparison is also made 
between TPEF image of (e) human skin and (f) porcine skin. Red: keratin 
(excitation: 780nm, emission: 525±35nm). Green: collagen (excitation: 
1020nm, emission: 525±35nm). 
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APPENDIX D: COMPLETE LIST OF SYSTEM COMPONENTS  
Table D.1 A summary of the system components. Hardware abbreviations can be 
found in Figure 2.1.  
Hardware Description Part Number Manufacturer 
Laser 830nm free-space single 
mode diode laser, maximum 
power 200mW 
LM830-PLR 200 
The new version 
was degraded to 
170mw 
Ondax 
CF 830nm Maxline laser clean-up 
filter 
LL01-830-25 Semrock 
OI Free space isolator, 830nm IO-3D-830-VLP Thorlabs 
Mirrors Protected silver mirror, 1” ME1-P01 Thorlabs 
SF Spatial filter system (L1, P1, 
& L2) 
KT310 Thorlabs 
L1 Aspheric lens, f = 11mm A397TM-B Thorlabs 
P1 25um pinhole P25S Thorlabs 
L2 Achromatic doublet, f = 
25mm 
AC254-025-B-
ML 
Thorlabs 
D1, D2 830 nm LPF, RazorEdge 
Dichroic laser-flat 
beamsplitter 
LPD01-830RU-
25x36x2.0 
 
Semrock 
GM 2D small beam diameter 
(<5mm) scanning galvo 
mirror systems 
GVSM002 Thorlabs 
L3 Achromatic doublet, f = 
100mm 
AC254-100-B-
ML 
Thorlabs 
L4 Achromatic doublet, f = 
200mm 
AC254-200-B-
ML 
Thorlabs 
FM 30 mm Cage Cube-Mounted 
Non-Polarizing Beamsplitter, 
700 - 1100 nm, 50:50 split 
ratio 
CM1-BS014 
 
Thorlabs 
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Table D.1 Continued. 
Microscope 
objective 
60x, NA = 1.2, WD = 
0.28mm, water 
UPLSAPO60XW
IR 
Olympus 
Low bgd Raman 
substrate 
Magnesium fluoride window  64-094 Edmund Optics 
Low bgd Raman 
substrate (for cell 
study) 
Quartz cover slip for 
microscope slide, fused, 1” 
dia, 0.15-0.25mm thick 
43211 Alfa Aesar 
  
  
Sample stage 
(manual 
translation), used 
for inverted 
objective setup 
Aperture platform two-Axis 
linear stage, 1/4-20 with two 
vernier micrometer, 13 mm 
Travel 
406 with SM-13 New Focus 
CMOS MP monochrome CMOS 
camera, 12-bit 
BTE-B050-U  Mightex 
Motorized 
Stage 
2-axis 1” motorized 
translation stage  
PT1-Z8  Thorlabs 
Axial translation 
(manual) 
1" Translation Stage with 
Standard Micrometer 
PT1 Thorlabs 
Notch filter 830nm, 25mm Diameter, OD 
4 Notch Filter 
86-703 
 
Edmund Optics 
 
L5, L6 Aspheric lens f = 18.4mm  Thorlabs 
P2, P3 50um fiber, NA = 0.22, multi-
mode, Low OH 
M14L01 Thorlabs 
Spectrograph Holographic Imaging 
Spectrograph  
HoloSpec f/1.8i - 
NIR 
Kaiser Optical 
Systems 
CCD Back-illuminated deep-
depletion CCD, Broad band 
UV-Near IR detection, 
1024x256 pixels 
Andor iDus 420, 
DU420ABEXDD 
Oxford 
Instruments 
Current 
preamplifier 
Low noise current 
preamplifier 
SR570 Stanford 
Research 
Systems 
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Table D.1 Continued.  
DAQ board Data acquisition board  PCIe-6351 National 
Instruments 
Future work    
Axial translation 
(autofocusing) 
NanoFlex 5 mm Translation 
Stage with Diff. Drive and 
Piezo 
NFL5DP20 
(already 
purchased) 
Thorlabs 
High-speed linear 
stage 
ProScan 121mm x 81mm 
travel DC linear motor stage 
for inverted microscope 
HLD117NN Prior Scientific 
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